0001213900-22-033764.txt : 20220621 0001213900-22-033764.hdr.sgml : 20220621 20220621085908 ACCESSION NUMBER: 0001213900-22-033764 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 39 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220621 DATE AS OF CHANGE: 20220621 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rasna Therapeutics Inc. CENTRAL INDEX KEY: 0001582249 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 392080103 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-191083 FILM NUMBER: 221026265 BUSINESS ADDRESS: STREET 1: 420 LEXINGTON AVENUE STREET 2: SUITE 2525 CITY: NEW YORK STATE: NY ZIP: 10170 BUSINESS PHONE: 646-396-4087 MAIL ADDRESS: STREET 1: 420 LEXINGTON AVENUE STREET 2: SUITE 2525 CITY: NEW YORK STATE: NY ZIP: 10170 FORMER COMPANY: FORMER CONFORMED NAME: Active With Me Inc. DATE OF NAME CHANGE: 20130723 10-Q 1 f10q0322_rasnatherap.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _______ to _______

Commission file number

333-191083

RASNA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada

39-2080103

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

420 Lexington Ave, Suite 2525, New York, NY 10170

(Address of principal executive offices) (Zip Code)

Telephone: (646) 396-4087

(Registrant’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act: None

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 179,979,361 shares of common stock were issued and outstanding as of June 16, 2022.

TABLE OF CONTENTS

		PAGE
PART 1	FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS (Unaudited)	1
	Condensed Consolidated Balance Sheets - March 31, 2022 and September 30, 2021	1
	Condensed Consolidated Statements of Operations for the Three and Six Months Ended March 31, 2022 and 2021	2
	Condensed Consolidated Statements of Changes in Shareholders’ Equity/(Deficit) for the Three and Six Months Ended March 31, 2022 and 2021	3
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended March 31, 2022 and 2021	4
	Notes to the Unaudited Condensed Consolidated Financial Statements	5
ITEM 2.	Management’s discussion and analysis of financial condition and results of operations	11
ITEM 3.	Controls and Procedures	17

PART II	OTHER INFORMATION

ITEM 1A	Risk factors	18
ITEM 6.	Exhibits	18
SIGNATURES		19

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

RASNA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	March 31, 2022			September 30, 2021
ASSETS
Current assets:
Cash	$	28,078		$	10,848
Prepaid expenses		7,620			33,729
Total assets	$	35,698		$	44,577

LIABILITIES AND SHAREHOLDERS’ DEFICIT

Liabilities:
Current liabilities:
Accounts payable and accrued expenses	$	1,407,802		$	1,516,001
Related party payables		200,822			561,446
Loan payable and accrued interest, related party		83,520			80,640
Convertible notes payable, net - related party		104,025			230,287
Convertible notes payable, net		303,933			371,997
Derivative liabilities		73,569			38,018
Total Current Liabilities		2,173,671			2,798,389

Commitments and contingencies

Shareholders’ deficit
Common stock, $0.001 par value; 200,000,000 shares authorized; 68,908,003 shares issued and outstanding		68,909			68,909
Additional paid-in capital		21,308,238			20,711,758
Accumulated deficit		(23,515,120	)		(23,534,479	)
Total shareholders’ deficit		(2,137,973	)		(2,753,812	)
Total liabilities and shareholders’ deficit	$	35,698		$	44,577

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

RASNA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	For the Three Months Ended March 31,						For the Six Months Ended March 31,
	2022			2021			2022			2021
Revenue	$	—		$	—		$	—		$	—
Cost of revenue		—			—			—			—
Gross profit		—			—			—			—

Operating (income)/ expenses:
General and administrative		126,041			77,555			198,697			203,824
Research and development		17,224			16,067			26,359			44,739
Gain on settlement of accounts payable		(150,000	)		—			(150,000	)		—
Gain on settlement of related party payable		(375,000	)		—			(375,000	)		—
Total operating (income)/ expenses		(381,735	)		93,622			(299,944	)		248,563

Income/ (loss) from operations		381,735			(93,622	)		299,944			(248,563	)

Other income/(expense):
Accretion of debt discount		(77,153	)		(27,273	)		(280,553	)		(27,273	)
Expenses in connection with modification and extinguishment of convertible promissory notes		—			(123,718	)		—			(123,718	)
Interest expense		(20,706	)		(21,640	)		(39,001	)		(38,716	)
Gain on derivative liability		10,114			—			38,969			—
Foreign currency transaction (loss)/gain		—			(107	)		—			48
Total other income/(expense)		(87,745	)		(172,738	)		(280,585	)		(189,659	)

Income/ (loss) from operations before income taxes		293,990			(266,360	)		19,359			(438,222	)

Income tax provision		—			—			—			—

Net income / (loss)	$	293,990		$	(266,360	)	$	19,359		$	(438,222	)

Basic and net income/(loss) per share attributable to common shareholders	$	0.00		$	0.00		$	0.00		$	(0.01	)
Diluted net income/ (loss) per share attributable to common shareholders	$	0.00		$	0.00		$	0.00		$	(0.01	)

Basic weighted average common shares outstanding		68,908,003			68,908,003			68,908,003			68,908,003
Diluted weighted average common shares outstanding		170,038,369			68,908,003			163,241,111			68,908,003

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

RASNA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY/(DEFICIT)

(UNAUDITED)

	Three Months Ended March 31, 2022
	Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Capital		Deficit			Deficit
Balance at December 31, 2021		68,908,003	$	68,909	$	21,236,238	$	(23,809,110	)	$	(2,503,963	)

Beneficial conversion feature related to convertible notes		—		—		72,000		—			72,000
Net income		—		—		—		293,990			293,990

Balance at March 31, 2022		68,908,003	$	68,909	$	21,308,238	$	(23,515,120	)	$	(2,137,973	)

	Three Months Ended March 31, 2021
	Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Capital		Deficit			Deficit
Balance at December 31, 2020		68,908,003	$	68,909	$	19,933,076	$	(22,830,343	)	$	(2,828,358	)

Share based compensation		—		—		17,796		—			17,796
Beneficial conversion feature related to convertible notes		—		—		273,718		—			273,718
Net loss		—		—		—		(266,360	)		(266,360	)

Balance at March 31, 2021		68,908,003	$	68,909	$	20,224,590	$	(23,096,703	)	$	(2,803,204	)

	Six Months Ended March 31, 2022
	Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Capital		Deficit			Deficit
Balance at October 1, 2021		68,908,003	$	68,909	$	20,711,758	$	(23,534,479	)	$	(2,753,812	)

Beneficial conversion feature related to convertible notes		—		—		596,480		—			596,480
Net income		—		—		—		19,359			19,359

Balance at March 31, 2022		68,908,003	$	68,909	$	21,308,238	$	(23,515,120	)	$	(2,137,973	)

	Six Months Ended March 31, 2021
	Common Stock				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Capital		Deficit			Deficit
Balance at October 1, 2020		68,908,003	$	68,909	$	19,914,884	$	(22,658,481	)	$	(2,674,688	)

Share based compensation		—		—		35,988		—			35,988
Beneficial conversion feature related to convertible notes						273,718					273,718
Net loss		—		—		—		(438,222	)		(438,222	)
Balance at March 31, 2021		68,908,003	$	68,909	$	20,224,590	$	(23,096,703	)	$	(2,803,204	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

RASNA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Six Months Ended March 31,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income/(loss)	$	19,359			(438,222	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation		—			35,988
Depreciation		—			314
Non-cash interest expense		39,002			2,880
Accretion of debt discount		280,553			27,273
Gain on derivative liability		(38,969	)		—
Fee for convertible loan note to be settled in equity		—			123,718
Gain on settlement of accounts payable		(150,000	)		—
Gain on settlement of related party payable		(375,000	)		—
Changes in operating assets and liabilities:
Accounts payable and accrued expenses		41,801			105,613
Related party payable		14,376			13,413
Prepaid expenses		26,108			(43,762	)
Related party receivable		—			748
Net cash used in operating activities		(142,770	)		(172,037	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes payable		160,000			190,000

Net change in cash		17,230			17,963

Cash, beginning of period		10,848			14,241

Cash, end of period	$	28,078			32,204
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Derivative liabilities in connection with issuance and extension of convertible notes	$	74,520		$	—
Beneficial conversion feature related to issuance and extension of convertible notes	$	596,481		$	—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

RASNA THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

1. GENERAL INFORMATION

Rasna Therapeutics, Inc. “Rasna Inc.” or the “Company”), is a biotechnology company incorporated in the State of Delaware on March 28, 2016. The Company is engaged in modulating the molecular targets NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma.

These unaudited condensed consolidated financial statements are presented in United States dollars (“USD”) which is also the functional currency of the primary economic environment in which the Company operates.

Risks and Uncertainties

Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or ability to secure additional cash resources, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

2. ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these unaudited condensed consolidated financial statements are set out below. These policies have been applied consistently to all the periods presented unless otherwise stated. There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s annual report on Form 10-K/A for the year ended September 30, 2021.

Basis of preparation

These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (the “SEC”) and United States generally accepted accounting principles (“US GAAP”) for interim reporting. The principles for condensed interim financial information do not require the inclusion of all the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements as of and for the year ended September 30, 2021 and notes thereto included in the Company’s Annual Report on Form 10-K/A filed with the SEC on June 9, 2022. The accompanying unaudited condensed consolidated financial statements have not been audited by an independent registered public accounting firm in accordance with the standards of the Public Company Accounting Oversight Board (United States), but in the opinion of management, such financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information.

The results of the operations for the three and six months ended March 31, 2022 may not be indicative of the results that may be expected for the year ending September 30, 2022.

Principles of Consolidation

The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, Rasna Research Inc, and Rasna Research Inc’s subsidiary, Arna Therapeutics Limited. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to the fair values of share based awards, income taxes and contingent liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates and such differences could be material to the Company’s consolidated financial position and results of operations.

Net Income/(loss) per Share

Basic net income/(loss) per share is computed by dividing net income/(loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted income per share includes potentially dilutive securities such as outstanding options, warrants and convertible loan notes, using various methods such as the treasury stock, modified treasury stock, and if converted methods in the determination of dilutive shares outstanding during each reporting period. Common stock equivalents are included in the diluted income per share calculation only when exercise or conversion prices are lower than the average market price of the common shares for the periods presented. This does not apply to the diluted loss per share calculation.

Diluted loss per share does not include any common stock equivalents as their effects are anti-dilutive.

The fully diluted earnings per share includes the shares issuable upon the conversion of the outstanding convertible loan notes for the three and six months to March 31, 2022.

	Three months March 31, 2022		Six months March 31, 2022
Net Income, numerator, basic computation		293,990		19,359
Interest expense		19,266		36,122
Net Income, numerator, diluted computation		313,256		55,481

Weighted average shares, denominator, basic computation		68,908,003		68,908,003
Effect of convertible notes		101,130,366		94,333,108
Weighted average shares, denominator, diluted computation		170,038,369		163,241,111

Earnings per share:
Basic		0.00		0.00
Diluted		0.00		0.00

The shares issuable on the exercise of options and warrants have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive.

	March 31, 2022		March 31, 2021
Stock options		3,648,675		3,648,675
Warrants		1,926,501		1,926,501
Convertible notes & associated fees		-		70,150,898
Total shares issuable upon exercise or conversion		5,575,176		75,726,074

Recent Accounting Pronouncements

In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company does not intend to early adopt and continues to evaluate the impact of the provisions of ASU 2020-06 on its consolidated financial statements.

The Company has determined that all other recently issued accounting pronouncements will not have a material impact on its consolidated financial position, results of operations and cash flows, or do not apply to its operations.

3. LIQUIDITY AND GOING CONCERN

The Company has no present revenue and has experienced net losses and significant cash outflows from cash used in operating activities since inception.

The Company is subject to a number of risks similar to those of other pre-commercial stage companies, including its dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with research, development, testing, and obtaining related regulatory approvals of its pipeline products, suppliers and collaborators, successful protection of intellectual property, competition with larger, better-capitalized companies, successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including obtaining adequate financing to fulfill its development activities and generating a level of revenues adequate to support the Company’s cost structure.

The Company has generally experienced net losses and significant cash outflows from cash used in operating activities over the past two years, and as of March 31, 2021, had an accumulated deficit of $23,515,120, a net income for the six months March 31, 2022 of $19,359 and net cash used in operating activities of $142,770.

The Company expects to continue to incur net losses and have significant cash outflows for at least the next 12 months and will require significant additional cash resources to launch new development phases of existing products in its pipeline.

In the event that the Company is unable to secure the additional cash resources needed, the Company may slow current development phases or halt new development phases in order to mitigate the effects of the costs of development. These conditions, among others, raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern one year from the date of this filing. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support the Company’s cost structure.

4. SHARE-BASED COMPENSATION

For the three and six months ended March 31, 2022 there have been no charges for share based compensation.

For the three and six months ended March 31, 2021, $17,796 and $35,988 related to share based compensation to directors and employees respectively, has been included within the general and administrative expense category in the accompanying unaudited condensed consolidated interim financial statements.

5. CONVERTIBLE NOTES

The table below summarizes outstanding convertible notes as of March 31, 2022 and March 31, 2021:

Balance of non-related notes payable, net as of September 30, 2021	$	371,997
Accrued Interest		14,847
Accretion of debt discount		152,090
Beneficial conversion feature related to issuance and extension of convertible notes		(206,801	)
Derivative liabilities in connection with issuance and extension of convertible notes		(28,200	)
Balance of non-related notes payable, net as of March 31, 2022	$	303,933

Balance of related party notes payable, net as of September 30, 2021	$	230,287
Issuance of debt		160,000
Accrued Interest		21,275
Accretion of debt discount		128,463
Beneficial conversion feature related to issuance and extension of convertible notes		(389,680	)
Derivative liabilities in connection with issuance and extension of convertible notes		(46,320	)
Balance of related notes payable, net as of March 31, 2022	$	104,025

Balance of related notes payable, net as of September 30, 2020	$	89,768
New convertible notes issued		190,000
Accrued Interest		10,392
Beneficial conversion feature related to issuance of convertible notes		(122,727	)
Balance of related notes payable, net as of March 31, 2021	$	167,433

Balance of non-related notes payable, net as of September 30, 2020	$	357,196
Accrued Interest		22,925
Balance of non-related notes payable, net as of March 31, 2021	$	380,121

On November 18, 2021, the Company entered into an eleventh 12% Convertible Promissory Note with Panetta Partners Ltd. (the “Holder”) with a maturity date of December 31, 2023. The Holder provided the Company with $30,000 in cash. The Note provides the Holder with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price equal to the lower of (i) $0.01 per share or (ii) the price of the next equity financing, which raises at least US $1,000,000, subject to adjustments noted within the Agreement. The number of shares issuable upon a conversion shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of the Note to be converted by (y) the Conversion Price. The Note requires the Company to reserve and keep available out of its authorized and unissued shares of common stock the amount of shares that would be issued upon conversion of the Note, which includes the outstanding principal amount of the Note and interest accrued and to be accrued through the date of maturity.

On November 29, 2021, the Company entered into the twelfth 12% Convertible Promissory Note again with Panetta Partners Ltd. (the “Holder”) pursuant to which the Company issued a Convertible Promissory Note to the Holder. The Holder provided the Company with $55,000 in cash. All other terms were the same as the eleventh note.

On February 8, 2022, the Company entered into the thirteenth 16% Convertible Promissory Note again with Panetta Partners Ltd. (the “Holder”) pursuant to which the Company issued a Convertible Promissory Note to the Holder. The Holder provided the Company with $30,000 in cash. The Note provides the Holder with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price equal to the lower of (i) $0.005 per share or (ii) the price of the next equity financing, which raises at least US $1,000,000, subject to adjustments noted within the Agreement. The number of shares issuable upon a conversion shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of the Note to be converted by (y) the Conversion Price. The Note requires the Company to reserve and keep available out of its authorized and unissued shares of common stock the amount of shares that would be issued upon conversion of the Note, which includes the outstanding principal amount of the Note and interest accrued and to be accrued through the date of maturity.

On March 2, 2022, the Company entered into the fourteenth 16% Convertible Promissory Note again with Panetta Partners Ltd. (the “Holder”) pursuant to which the Company issued a Convertible Promissory Note to the Holder. The Holder provided the Company with $45,000 in cash. All other terms were the same as the thirteenth note.

Amendment

On December 31, 2021, all previously outstanding notes due December 31, 2021 were modified with amended expiry terms. The expiry of the notes was amended to December 31, 2023.

The Company determined that the extension of maturity dates resulted in extinguishment for Notes carrying interest at 12%, while the Notes carrying interest at 1% resulted in modification.

The Company measured the present value of future cash flows that existed just prior to the earliest restructuring in the twelve-month period, which was used to apply the 10% test, since the earlier restructurings was accounted for as a modification. As the change in cash flows for all Notes carrying interest at 12% was greater than 10%, the term amendment was accounted for as an extinguishment. Under extinguishment accounting, the debt was remeasured and recorded at fair value. There was no difference between the carrying value of the debt, prior to the extinguishment, and the new fair value of the debt.

The Notes carrying interest at 1% did not have a change in cash flows greater than 10%, so these Notes were accounted for as a modification.

The Company also noted that the stock was thinly traded with any trading activity resulting in a disproportionate effect on the stock price. Therefore, a Black Scholes valuation was deemed to be inappropriate in this case.

Embedded Derivative Liability

Under the promissory note agreement, the interest rate will reset upon the event of a default and an additional penalty of 6% will be accrued. The Company analyzed the conversion features of the note agreement for derivative accounting consideration under ASC 815, Derivatives and Hedging, and determined the interest rate resets met the definition of a derivative. It also noted that the Contingent Interest Rate feature required bifurcation from the host note contract and was to be accounted for at fair value. In accordance with ASC 815-15, the Company bifurcated the Contingent Interest Rate feature of the note and recorded a derivative liability.

The embedded derivatives for the notes are carried on the Company’s balance sheet at fair value. During the three and six months to March 31, 2021, the Company recognized an additional $3,000 and $71,520 respectively due to the extension and issuance of the convertible notes. Additionally, the Company recognized a gain of $10,114 and $38,969 for the three and six month periods ended March 31, 2022, relating to the issuance and extension of convertible notes.

Beneficial Conversion Feature

The conversion features for all notes issued are in the money as of the issuance date and accordingly a beneficial conversion feature was recorded upon issuance. As the intrinsic value of the Beneficial Conversion Feature exceeds the face value, the recorded Beneficial Conversion Feature will be limited to the gross proceeds less any debt discounts. As at March 31, 2022 this amounted to $596,481 for the amended and new notes issued.

6. RELATED PARTY TRANSACTIONS

The following is a summary of the related party transactions for the periods presented.

Eurema Consulting

Eurema Consulting S.r.l. is a significant shareholder of the Company. During the three and six months ended March 31, 2022 and March 31, 2021 Eurema Consulting did not supply the Company with consulting services.

In March 2022, the Company agreed to return back to Eurema Consulting S.R.L all intellectual property rights and assignments relating to NPM1. In exchange for this, Eurema Consulting S.R.L agreed to waive any payments due to them and their affiliates by Rasna, this amounted to a $200,000 gain on the settlement of the related party payable. Rasna may be entitled to 20% of any future royalties and/or milestone payments upon successful completion of a clinical Proof of Concept study under certain agreed upon circumstances.

As of March 31, 2022, and September 30, 2021, the balance due to Eurema Consulting S.r.l. was $0 and $200,000, respectively for past consultancy services.

Gabriele Cerrone

Gabriele Cerrone is the majority shareholder of Panetta Partners, one of the Company’s principal shareholders. As of March 31, 2022, and September 30, 2021, the balance due to Gabriele Cerrone was $175,000 for past consultancy services.

In March 2020, the Company entered into a 12% Convertible Promissory Note with Gabriele Cerrone for $20,000 with an extended maturity date of December 31, 2023. In February 2021, Gabriele Cerrone assigned the Note to Panetta Partners Ltd. In November 2021, the Company entered into two 12% Convertible Promissory Notes with Panetta Partners Ltd for the aggregate amount of $85,000. In February and March 2022, the Company entered into a further two 16% Convertible Promissory Notes with Panetta Partners Ltd for the $30,000 and $45,000 respectively.

Roberto Pellicciari and TES Pharma

Roberto Pellicciari is the majority shareholder of TES Pharma Srl, one of the Company’s principal shareholders. During the three and six months ended March 31, 2022 and March 31, 2021, Roberto Pellicciari did not supply the Company with consulting services.

In March 2022, the Company agreed to return back to TES Pharma S.R.L all intellectual property rights and assignments relating to NPM1. In exchange for this, TES Pharma S.R.L agreed to waive any payments due to them and their affiliates (which includes Roberto Pelliciari) by Rasna. this amounted to a $175,000 gain on the settlement of the related party payable to Roberto Pellicciari and a $150,000 gain on the settlement of accounts payable to TES Pharma and its affiliates. Rasna may be entitled to 20% of any future royalties and/or milestone payments upon successful completion of a clinical Proof of Concept study under certain agreed upon circumstances.

As of March 31, 2022, and September 30, 2021, the balance due to Roberto Pellicciari was $0 and $175,000 respectively, for past consultancy services. At March 31, 2022 and September 30, 2021, TES Pharma was owed $0 and $75,000 respectively.

Tiziana Life Sciences Plc (“Tiziana”)

The Company is party to a Shared Services Agreement with Tiziana, whereby the Company is charged for shared services and rent. Tiziana had previously agreed to waive all charges for shared services from October 2018 onwards, until further notice since the amounts due for such services are de minimis. Notice was given and recharges from October 1, 2020 were resumed. Keeren Shah, the Company’s Finance Director, is also Finance Director of Tiziana, and the Company’s directors, Willy Simon and John Brancaccio are also non-executive directors of Tiziana.

As of March 31, 2022, $25,822 was due to Tiziana under services charged under the shared services agreement. This is recorded as a related party payable in the accompanying condensed consolidated balance sheets.

In March 2020, Tiziana extended a loan facility to Rasna of $65,000. The loan is repayable within 18 months and is incurring an interest charge of 8% per annum. In April 2020, the loan facility was extended by a further $7,000, so the loan facility totals $72,000. As of March 31, 2022, the amounts due to Tiziana under this loan facility were $83,520 and the interest charged in the three and six months to March 31, 2021, was $1,440 and $2,880 respectively.

Panetta Partners

Panetta Partners Limited, a shareholder of Rasna, is a company in which Gabriele Cerrone is a major shareholder and also serves as a director. The Company has entered into numerous 12% Convertible Promissory Notes with Panetta Partners for a total of $361,000. The amount due for these notes as at March 31, 2022, with respect to the principal and accrued interest is $462,842, net of debt discounts of $358,817 . As at September 30, 2021 $276,303 was due with respect to notes issued.

Apart from the Convertible Promissory Notes, there is no interest charged on the balances with related parties. There are no defined repayment terms and such amounts can be called for payment at any time.

7. SUBSEQUENT EVENTS

On May 13, 2022, the Company received notice from all noteholders that all notes were to be converted into stock. The Company issued 111,071,358 of common stock on May 13, 2022 in respect of these conversions.

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This section and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Forward-looking statements are not guarantees of future performance and the Company’s actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in the Company’s Annual Report on Form 10-K filed on January 15, 2021 under the heading “Risk Factors,” which are incorporated herein by reference.

We assume no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Unless expressly indicated or the context requires otherwise, the terms “Rasna,”,” the “Company,” “we,” “us,” and “our” refer to Rasna Therapeutics, Inc., a Nevada corporation, and, where appropriate, its wholly owned subsidiaries.

Company Background

To date, we have devoted substantially all of our resources to research and development efforts relating to our therapeutic candidates, including conducting clinical trials and developing manufacturing capabilities, in-licensing related intellectual property, protecting our intellectual property and providing general and administrative support for these operations. Since our inception, we have funded our operations primarily through the issuance of equity securities and convertible notes.

We anticipate that our expenses will increase substantially if and as we:

	●	initiate new clinical trials;

	●	seek to identify, assess, acquire and develop other products, therapeutic candidates and technologies;

	●	seek regulatory and marketing approvals in multiple jurisdictions for our therapeutic candidates that successfully complete clinical studies;

	●	establish collaborations with third parties for the development and commercialization of our products and therapeutic candidates;

	●	make milestone or other payments under our agreements pursuant to which we have licensed or acquired rights to intellectual property and technology;

	●	seek to maintain, protect, and expand our intellectual property portfolio;

	●	seek to attract and retain skilled personnel;

	●	incur the administrative costs associated with being a public company and related costs of compliance;

	●	create additional infrastructure to support our operations as a commercial stage public company and our planned future commercialization efforts; and

	●	experience any delays or encounter issues with any of the above.

We expect to continue to incur significant expenses and increasing losses for at least the next several years. Accordingly, we anticipate that we will need to raise additional capital in addition to the net proceeds from this offering in order to obtain regulatory approval for, and the commercialization of our therapeutic candidates. Until such time that we can generate meaningful revenue from product sales, if ever, we expect to finance our operating activities through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or a combination of these approaches. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any approved therapies or products or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially adversely affect our business, financial condition and results of operations.

We only have one segment of activity, which is that of a biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia and lymphoma.

The Company is currently looking into raising funds to progress its R&D pipeline.

Critical Accounting Policies and Estimates

This discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America, or US GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. In accordance with US GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

In December 2019, the FASB issued ASU 2019 -12, Income Taxes – Simplifying the Accounting for Income Taxes (“ASU 2019-12”). Among other items, the amendments in ASU 2019-12 simplify the accounting treatment of tax law changes and year-to-date losses in interim periods. An entity generally recognizes the effects of a change in tax law in the period of enactment; however, there is an exception for tax laws with delayed effective dates. Under current guidance, an entity may not adjust its annual effective tax rate for a tax law change until the period in which the law is effective. This exception was removed under ASU 2019-12, thereby providing that all effects of a tax law change are recognized in the period of enactment, including adjustment of the estimated annual effective tax rate. Regarding year-to-date losses in interim periods, an entity is required to estimate its annual effective tax rate for the full fiscal year at the end of each interim period and use that rate to calculate its income taxes on a year-to-date basis. However, current guidance provides an exception that when a loss in an interim period exceeds the anticipated loss for the year, the income tax benefit is limited to the amount that would be recognized if the year-to-date loss were the anticipated loss for the full year. ASU 2019-12 removes this exception and provides that, in this situation, an entity would compute its income tax benefit at each interim period based on its estimated annual effective tax rate. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those annual periods. Early adoption is permitted. The Company has determined that the effect of this amendment is immaterial on its financial statements and related disclosures.

Basis of preparation

The accompanying financial statements have been prepared in conformity with US GAAP. Any reference in these notes to applicable guidance is meant to refer to US GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“the FASB”).

Liquidity and Going Concern

We are subject to a number of risks similar to those of other pre-commercial stage companies, including our dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with research, development, testing, and obtaining related regulatory approvals of its pipeline products, suppliers and collaborators, successful protection of intellectual property, competition with larger, better-capitalized companies, successful completion of our development programs and, ultimately, the attainment of profitable operations are dependent on future events, including obtaining adequate financing to fulfill our development activities and generating a level of revenues adequate to support our cost structure.

We have no present revenue and have experienced net losses and significant cash outflows from cash used in operating activities since inception, and at March 31, 2022, had a working capital deficit of $2,137,973.

We expect to continue to incur net losses and have significant cash outflows for at least the next twelve months and will require significant additional cash resources to launch new development phases of existing products in its pipeline. In the event that the Company is unable to secure the necessary additional cash resources needed, we may slow current development phases or halt new development phases in order to mitigate the effects of the costs of development. These conditions, among others, raise substantial doubt about our ability to continue as a going concern one year from the date of this filing. The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern one year from the date of this filing. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support our cost structure.

Results of Operations

The following paragraphs set forth our results of operations for the periods presented. The period-to-period comparison of financial results is not necessarily indicative of future results.

Results of Operations for the Three months ended March 31, 2022 and 2021

The following table sets forth the summary statements of operations for the periods indicated:

	For the Three Months Ended March 31,
	2022			2021
	(Unaudited)			(Unaudited)
Revenue	$	—		$	—
Cost of revenue		—			—
Gross profit		—			—

Operating (income)/expenses:
General and administrative		126,041			77,555
Research and development		17,224			16,067
Gain on settlement of accounts payable		(150,000	)		—
Gain on settlement of related party payable		(375,000	)		—
Total operating (income)/ expenses		(381,735	)		93,622

Income/ (loss) from operations		381,735			(93,622	)

Other expense:
Accretion of debt discount		(77,153	)		(27,273	)
Expenses in connection with modification and extinguishment of convertible promissory notes		—			(123,718	)
Interest expense		(20,706	)		(21,640	)
Gain on derivative liability		10,114			—
Foreign currency transaction (loss)/gain		—			(107	)
Other expense		(87,745	)		(172,738	)

Net income/ (loss)	$	293,990		$	(266,360	)

Revenues

There were no revenues for the three months ended March 31 2022, and 2021 because the Company does not have any commercial biopharmaceutical products.

Operating Income/(Expenses)

Operating expenses, consisting of research and development costs, consultancy fees, legal and professional fees and general and administrative expenses, for the three months ended March 31, 2022 decreased to an operating income of $381,735 from an operating expense of $93,623 for the three months ended March 31, 2021, a decrease of $475,357. The decrease is predominantly due to a $150,000 and $375,000 gain on the settlement of accounts payable and related party payable, respectively, due to the release of payment obligations to TES Pharma S.R.L and Eurema Consulting S.R.L (and their affiliates) as all intellectual property rights and assignments relating to NPM1 were returned to them by the Company, offset by increased general and administrative expenditure of $38,095 and increased research and development patent expenditure of $11,547.

Other expense

During the six months ended March 31, 2022, other expense decreased to $87,745 from $172,738 for the three months ended March 31, 2021. This is predominantly due to additional accretion of debt discount by $49,880 offset by a gain on the adjustment of a derivative liability of $10,114 and a saving on expenses in connection with modification and extinguishment of convertible promissory notes in 2021 of $123,718.

Net Income/(Loss)

Net income for the three months ended March 31, 2022 increased to $293,990 from a net loss of $266,360 for the three months ended March 31, 2021, a movement of $560,350. This is predominantly due to $150,000 and $375,000 gain on the settlement of accounts payable and related party payable, respectively, due to the release of payment obligations to TES Pharma S.R.L and Eurema Consulting S.R.L (and their affiliates) as all intellectual property rights and assignments relating to NPM1 were returned to them by the Company.

Results of Operations for the Six months ended March 31, 2022 and 2021

The following table sets forth the summary statements of operations for the periods indicated:

	For the Six Months Ended March 31,
	2022			2021
	(Unaudited)			(Unaudited)
Revenue	$	—		$	—
Cost of revenue		—			—
Gross profit		—			—

Operating (income)/expenses:
General and administrative		198,697			203,824
Research and development		26,359			44,739
Gain on settlement of accounts payable		(150,000	)		—
Gain on settlement of related party payable		(375,000	)		—
Total operating (income)/ expenses		(299,944	)		248,563

Income/ (loss) from operations		299,944			(248,563	)

Other expense:
Accretion of debt discount		(280,552	)		(27,273	)
Expenses in connection with modification and extinguishment of convertible promissory notes		—			(123,718	)
Interest expense		(39,002	)		(38,716	)
Gain on derivative liability		38,969			—
Foreign currency transaction (loss)/gain		—			48
Other expense		(280,585	)		(189,659	)

Net income/ (loss)	$	19,359		$	(438,222	)

Revenues

There were no revenues for the six months ended March 31 2022, and 2021 because the Company does not have any commercial biopharmaceutical products.

Operating Income/(Expenses)

Operating expenses, consisting of research and development costs, consultancy fees, legal and professional fees and general and administrative expenses, for the six months ended March 31, 2022 decreased to an operating income of $299,944 from an operating expense of $248,563 for six months ended March 31, 2021, a decrease of $548,507. The decrease is predominantly due to a $150,000 and $375,000 gain on the settlement of accounts payable and related party payable, respectively, due to the release of payment obligations to TES Pharma S.R.L and Eurema Consulting S.R.L (and their affiliates) as all intellectual property rights and assignments relating to NPM1 were returned to them by the Company, offset by decreased general and administrative expenditure of $5,127 and decreased research and development patent expenditure of $18,380.

Other expense

During the six months ended March 31, 2022, other expense increased to $280,585 from $189,659 for the six months ended March 31, 2021. This is predominantly due to additional accretion of debt discount by $253,279 offset by a gain on the adjustment of a derivative liability of $38,969 and a saving on expenses in connection with modification and extinguishment of convertible promissory notes incurred in 2021 of $123,718.

Net Income/(Loss)

Net income for the six months ended March 31, 2022 increased to $19,359 from a net loss of $438,222 for the six months ended March 31, 2021, a movement of $457,581. This is predominantly due to $150,000 and $375,000 gain on the settlement of accounts payable and related party payable, respectively, due to the release of payment obligations due to TES Pharma S.R.L and Eurema Consulting S.R.L (and their affiliates) as all intellectual property rights and assignments relating to NPM1 were returned to them by the Company.

Liquidity and Capital Resources

We believe we will require significant additional cash resources to continue to launch new development phases of existing products in the Company’s pipeline. In the event that we are unable to secure the necessary additional cash resources needed, we may slow current development phases or halt new development phases in order to mitigate the effects of the costs of development. These conditions, among others, raise substantial doubt about our ability to continue as a going concern. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support our cost structure. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our shareholders may experience significant dilution. Any debt financing, if available, may (i) involve restrictive covenants that impact our ability to conduct, delay, scale back or discontinue the development and/or commercialization of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize its self on unfavorable terms.

On November 29, 2021, the Company entered into another 12% Convertible Promissory Note again with Panetta Partners Ltd. (the “Holder”) pursuant to which the Company issued a Convertible Promissory Note to the Holder. The Holder provided the Company with $55,000 in cash. All other terms were the same as the note before.

Capital Resources

The following table summarizes total current assets, liabilities and working capital deficiency as of the periods indicated:

	March 31, 2022 (Unaudited)			September 30, 2021 (Unaudited)			Change

Current assets	$	35,698		$	44,577		$	(8,879	)
Current liabilities		2,173,671			2,798,389			624,718
Working capital deficit	$	(2,137,973	)	$	(2,753,812	)	$	615,839

We had a cash balance of $28,078 and $10,848 on March 31, 2022, and September 30, 2021, respectively.

Liquidity

The following table sets forth a summary of our cash flows for the periods indicated:

	For the Six months ended March 31,
	2022			2021			Increase/ (Decrease)
Net cash used in operating activities	$	(142,770	)		(172,037	)		(29,267	)
Net cash used in investing activities	$	-			-			-
Net cash provided by financing activities	$	160,000			190,000			(30,000	)

Net Cash Used in Operating Activities

Net cash used in operating activities consists of net loss adjusted for the effect of changes in operating assets and liabilities.

Net cash used in operating activities was $142,770 for the six months ended March 31, 2022 compared to $172,037 for the six months ended March 31, 2021. The net income of $19,359 for six months ended March 31, 2022 was partially offset primarily by interest expense of $39,002, accretion of debt discount of $280,553, gain on derivative liability of ($38,969), gain on the settlement of accounts payable of $150,000 and a gain on the settlement of a related party payable of $375,000 and changes in operating assets and liabilities of $82,285.

Net Cash Provided by Financing Activities

Net cash provided by financing activities consists of proceeds from the issuance of convertible notes of $160,000 for the six months ended March 31, 2022 compared to proceeds from the issuance of convertible notes of $190,000 for the six months ended March 31, 2021.

ITEM 3. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This term refers to the controls and procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized, and reported within the required time periods. In designing and evaluating our disclosure controls and procedures, our management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

As of the end of the period covered by this Report, the Company’s Chief Executive Officer, evaluated the effectiveness of the Company’s “disclosure controls and procedures,” as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Based on that evaluation, the Chief Executive officer concluded that, as of the date of the evaluation, the Company’s disclosure controls and procedures were not effective to provide reasonable assurance that the information required to be disclosed in the Company’s periodic filings under the Securities Exchange Act of 1934 is accumulated and communicated to management to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act) during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K as of and for the year ended September 30, 2020, filed with the SEC on February 15, 2021.

ITEM 6. EXHIBITS

31.1		Certification of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.
32.1		Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 906 of Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Rasna Therapeutics, Inc.

June 21, 2022	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer, (Principal Executive Officer and Principal Financial and Accounting Officer)

EX-31.1 2 f10q0322ex31-1_rasnatherap.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL AND
ACCOUNTING OFFICER

I, Keeren Shah, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Rasna Therapeutics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: June 21, 2022


/s/ Keeren Shah
Name:	Keeren Shah
Title:	Principal Executive Officer and Principal Financial and Accounting Officer

EX-32.1 3 f10q0322ex32-1_rasnatherap.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Rasna Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Keeren Shah, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Dated: June 21, 2022


/s/ Keeren Shah
Name:	Keeren Shah
Title:	Principal Executive Officer and Principal Financial Officer

EX-101.SCH 4 rasp-20220331.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Changes in Shareholders’ Equity/(Deficit) (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - General Information link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Liquidity and Going Concern link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Share-Based Compensation link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Convertible Notes link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Convertible Notes (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Accounting Policies (Details) - Schedule of conversion of the outstanding convertible loan notes link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Accounting Policies (Details) - Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Liquidity and Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Share-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Convertible Notes (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Convertible Notes (Details) - Schedule of convertible notes link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 5 rasp-20220331_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 rasp-20220331_def.xml XBRL DEFINITION FILE EX-101.LAB 7 rasp-20220331_lab.xml XBRL LABEL FILE Statement of Financial Position [Abstract] Total assets Total Current Liabilities Total shareholders’ deficit Balance Balance Total liabilities and shareholders’ deficit Income Statement [Abstract] Gross profit Total operating (income)/ expenses Income/ (loss) from operations Total other income/(expense) Income/ (loss) from operations before income taxes Net income / (loss) Net income/(loss) Statement of Stockholders' Equity [Abstract] Balance (in Shares) Balance (in Shares) Equity Components [Axis] Statement of Cash Flows [Abstract] Net cash used in operating activities Net change in cash Cash, beginning of period Cash, end of period Accounting Policies [Abstract] Schedule of conversion of the outstanding convertible loan notes [Abstract] Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants [Abstract] Option Indexed to Issuer's Equity [Axis] Organization, Consolidation and Presentation of Financial Statements [Abstract] Share-Based Payment Arrangement [Abstract] Convertible Notes [Abstract] Schedule of convertible notes [Abstract] Related Party Transaction [Axis] Beginning balance Ending balance Related Party Transactions [Abstract] Subsequent Events [Abstract] Document Type Document Quarterly Report Document Period End Date Document Fiscal Year Focus Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Entity Central Index Key ASSETS Current assets: Cash Prepaid expenses LIABILITIES AND SHAREHOLDERS’ DEFICIT Liabilities: Current liabilities: Accounts payable and accrued expenses Related party payables Loan payable and accrued interest, related party Convertible notes payable, net - related party Convertible notes payable, net Derivative liabilities Derivative liabilities in connection with issuance and extension of convertible notes Commitments and contingencies Shareholders’ deficit Common stock, $0.001 par value; 200,000,000 shares authorized; 68,908,003 shares issued and outstanding Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid-in capital Accumulated deficit Revenue Cost of revenue Operating (income)/ expenses: General and administrative Research and development Other income/(expense): Expenses in connection with modification and extinguishment of convertible promissory notes Interest expense Gain on derivative liability Foreign currency transaction (loss)/gain Income tax provision Basic and net income/(loss) per share attributable to common shareholders (in Dollars per share) Basic Diluted net income/ (loss) per share attributable to common shareholders (in Dollars per share) Diluted Basic weighted average common shares outstanding (in Shares) Diluted weighted average common shares outstanding (in Shares) Beneficial conversion feature related to convertible notes Net income (loss) Net income Share based compensation CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Share based compensation Depreciation Non-cash interest expense Accretion of debt discount Gain on derivative liability Issuance of debt Fee for convertible loan note to be settled in equity Changes in operating assets and liabilities: Accounts payable and accrued expenses Related party payable CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of convertible notes payable SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Derivative liabilities in connection with issuance and extension of convertible notes Beneficial conversion feature related to issuance and extension of convertible notes Gain on settlement of accounts payable Gain on settlement of related party payable Accretion of debt discount Prepaid expenses Related party receivable Common Stock Additional Paid-In Capital Accumulated Deficit GENERAL INFORMATION ACCOUNTING POLICIES Schedule of conversion of the outstanding convertible loan notes Net Income, numerator, basic computation Interest expense Net Income, numerator, diluted computation Weighted average shares, denominator, basic computation Effect of convertible notes Weighted average shares, denominator, diluted computation Earnings per share: Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants Total shares issuable upon exercise or conversion LIQUIDITY AND GOING CONCERN SHARE-BASED COMPENSATION CONVERTIBLE NOTES Schedule of convertible notes Accrued Interest Accretion of debt discount Beneficial conversion feature related to issuance and extension of convertible notes New convertible notes issued RELATED PARTY TRANSACTIONS SUBSEQUENT EVENTS Stock options [Member] Warrants [Member] Convertible notes & associated fees [Member] Non-related notes payable [Member] Related party notes payable [Member] Related Party [Axis] Long-Term Debt, Type [Axis] Counterparty Name [Axis] Scenario [Axis] Accumulated deficit Share based compensation to directors Share based compensation to employees Percentage of convertible promissory note Maturity date Cash Expiry date EX-101.PRE 8 rasp-20220331_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Mar. 31, 2022	Jun. 16, 2022
Document Information Line Items
Entity Registrant Name	Rasna Therapeutics Inc.
Document Type	10-Q
Current Fiscal Year End Date	--09-30
Entity Common Stock, Shares Outstanding		179,979,361
Amendment Flag	false
Entity Central Index Key	0001582249
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	333-191083
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	39-2080103
Entity Address, Address Line One	420 Lexington Ave
Entity Address, Address Line Two	Suite 2525
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10170
City Area Code	(646)
Local Phone Number	396-4087
Entity Interactive Data Current	Yes

XML 10 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Sep. 30, 2021
Current assets:
Cash	$ 28,078	$ 10,848
Prepaid expenses	7,620	33,729
Total assets	35,698	44,577
Current liabilities:
Accounts payable and accrued expenses	1,407,802	1,516,001
Related party payables	200,822	561,446
Loan payable and accrued interest, related party	83,520	80,640
Convertible notes payable, net - related party	104,025	230,287
Convertible notes payable, net	303,933	371,997
Derivative liabilities	73,569	38,018
Total Current Liabilities	2,173,671	2,798,389
Commitments and contingencies
Shareholders’ deficit
Common stock, $0.001 par value; 200,000,000 shares authorized; 68,908,003 shares issued and outstanding	68,909	68,909
Additional paid-in capital	21,308,238	20,711,758
Accumulated deficit	(23,515,120)	(23,534,479)
Total shareholders’ deficit	(2,137,973)	(2,753,812)
Total liabilities and shareholders’ deficit	$ 35,698	$ 44,577

XML 11 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2022	Sep. 30, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	68,908,003	68,908,003
Common stock, shares outstanding	68,908,003	68,908,003

XML 12 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Revenue
Cost of revenue
Gross profit
Operating (income)/ expenses:
General and administrative	126,041	77,555	$ 198,697	$ 203,824
Research and development	17,224	16,067	26,359	44,739
Gain on settlement of accounts payable	(150,000)		(150,000)
Gain on settlement of related party payable	(375,000)		(375,000)
Total operating (income)/ expenses	(381,735)	93,622	(299,944)	248,563
Income/ (loss) from operations	381,735	(93,622)	299,944	(248,563)
Other income/(expense):
Accretion of debt discount	(77,153)	(27,273)	(280,553)	(27,273)
Expenses in connection with modification and extinguishment of convertible promissory notes		(123,718)		(123,718)
Interest expense	(20,706)	(21,640)	(39,001)	(38,716)
Gain on derivative liability	10,114		38,969
Foreign currency transaction (loss)/gain		(107)		48
Total other income/(expense)	(87,745)	(172,738)	(280,585)	(189,659)
Income/ (loss) from operations before income taxes	293,990	(266,360)	19,359	(438,222)
Income tax provision
Net income / (loss)	$ 293,990	$ (266,360)	$ 19,359	$ (438,222)
Basic and net income/(loss) per share attributable to common shareholders (in Dollars per share)	$ 0	$ 0	$ 0	$ (0.01)
Diluted net income/ (loss) per share attributable to common shareholders (in Dollars per share)	$ 0	$ 0	$ 0	$ (0.01)
Basic weighted average common shares outstanding (in Shares)	68,908,003	68,908,003	68,908,003	68,908,003
Diluted weighted average common shares outstanding (in Shares)	170,038,369	68,908,003	163,241,111	68,908,003

XML 13 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Shareholders’ Equity/(Deficit) (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Sep. 30, 2020	$ 68,909	$ 19,914,884	$ (22,658,481)	$ (2,674,688)
Balance (in Shares) at Sep. 30, 2020	68,908,003
Share based compensation		35,988		35,988
Beneficial conversion feature related to convertible notes		273,718		273,718
Net income (loss)			(438,222)	(438,222)
Balance at Mar. 31, 2021	$ 68,909	20,224,590	(23,096,703)	(2,803,204)
Balance (in Shares) at Mar. 31, 2021	68,908,003
Balance at Dec. 31, 2020	$ 68,909	19,933,076	(22,830,343)	(2,828,358)
Balance (in Shares) at Dec. 31, 2020	68,908,003
Share based compensation		17,796		17,796
Beneficial conversion feature related to convertible notes		273,718		273,718
Net income (loss)			(266,360)	(266,360)
Balance at Mar. 31, 2021	$ 68,909	20,224,590	(23,096,703)	(2,803,204)
Balance (in Shares) at Mar. 31, 2021	68,908,003
Balance at Sep. 30, 2021	$ 68,909	20,711,758	(23,534,479)	(2,753,812)
Balance (in Shares) at Sep. 30, 2021	68,908,003
Beneficial conversion feature related to convertible notes		596,480		596,480
Net income (loss)			19,359	19,359
Balance at Mar. 31, 2022	$ 68,909	21,308,238	(23,515,120)	(2,137,973)
Balance (in Shares) at Mar. 31, 2022	68,908,003
Balance at Dec. 31, 2021	$ 68,909	21,236,238	(23,809,110)	(2,503,963)
Balance (in Shares) at Dec. 31, 2021	68,908,003
Beneficial conversion feature related to convertible notes		72,000		72,000
Net income (loss)			293,990	293,990
Balance at Mar. 31, 2022	$ 68,909	$ 21,308,238	$ (23,515,120)	$ (2,137,973)
Balance (in Shares) at Mar. 31, 2022	68,908,003

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 14 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income/(loss)	$ 293,990	$ 19,359	$ (438,222)
Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation			35,988
Depreciation			314
Non-cash interest expense		39,002	2,880
Accretion of debt discount		280,553	27,273
Gain on derivative liability		(38,969)
Fee for convertible loan note to be settled in equity			123,718
Gain on settlement of accounts payable	(150,000)	(150,000)
Gain on settlement of related party payable	(375,000)	(375,000)
Changes in operating assets and liabilities:
Accounts payable and accrued expenses		41,801	105,613
Related party payable		14,376	13,413
Prepaid expenses		26,108	(43,762)
Related party receivable			748
Net cash used in operating activities		(142,770)	(172,037)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes payable		160,000	190,000
Net change in cash		17,230	17,963
Cash, beginning of period		10,848	14,241
Cash, end of period	$ 28,078	28,078	32,204
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Derivative liabilities in connection with issuance and extension of convertible notes		74,520
Beneficial conversion feature related to issuance and extension of convertible notes		$ 596,481

XML 15 R7.htm IDEA: XBRL DOCUMENT

General Information

6 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

GENERAL INFORMATION

1. GENERAL INFORMATION

Risks and Uncertainties

XML 16 R8.htm IDEA: XBRL DOCUMENT

Accounting Policies

6 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

ACCOUNTING POLICIES

2. ACCOUNTING POLICIES

Basis of preparation

The results of the operations for the three and six months ended March 31, 2022 may not be indicative of the results that may be expected for the year ending September 30, 2022.

Principles of Consolidation

Use of Estimates

Net Income/(loss) per Share

Diluted loss per share does not include any common stock equivalents as their effects are anti-dilutive.

The fully diluted earnings per share includes the shares issuable upon the conversion of the outstanding convertible loan notes for the three and six months to March 31, 2022.

	Three months March 31, 2022		Six months March 31, 2022
Net Income, numerator, basic computation		293,990		19,359
Interest expense		19,266		36,122
Net Income, numerator, diluted computation		313,256		55,481

Weighted average shares, denominator, basic computation		68,908,003		68,908,003
Effect of convertible notes		101,130,366		94,333,108
Weighted average shares, denominator, diluted computation		170,038,369		163,241,111

Earnings per share:
Basic		0.00		0.00
Diluted		0.00		0.00

The shares issuable on the exercise of options and warrants have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive.

	March 31, 2022		March 31, 2021
Stock options		3,648,675		3,648,675
Warrants		1,926,501		1,926,501
Convertible notes & associated fees		-		70,150,898
Total shares issuable upon exercise or conversion		5,575,176		75,726,074

Recent Accounting Pronouncements

XML 17 R9.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern

6 Months Ended

Mar. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

LIQUIDITY AND GOING CONCERN

3. LIQUIDITY AND GOING CONCERN

The Company has no present revenue and has experienced net losses and significant cash outflows from cash used in operating activities since inception.

XML 18 R10.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

6 Months Ended

Mar. 31, 2022

Share-Based Payment Arrangement [Abstract]

SHARE-BASED COMPENSATION

4. SHARE-BASED COMPENSATION

For the three and six months ended March 31, 2022 there have been no charges for share based compensation.

XML 19 R11.htm IDEA: XBRL DOCUMENT

Convertible Notes

6 Months Ended

Mar. 31, 2022

Convertible Notes [Abstract]

CONVERTIBLE NOTES

5. CONVERTIBLE NOTES

The table below summarizes outstanding convertible notes as of March 31, 2022 and March 31, 2021:

Balance of non-related notes payable, net as of September 30, 2021	$	371,997
Accrued Interest		14,847
Accretion of debt discount		152,090
Beneficial conversion feature related to issuance and extension of convertible notes		(206,801	)
Derivative liabilities in connection with issuance and extension of convertible notes		(28,200	)
Balance of non-related notes payable, net as of March 31, 2022	$	303,933

Balance of related party notes payable, net as of September 30, 2021	$	230,287
Issuance of debt		160,000
Accrued Interest		21,275
Accretion of debt discount		128,463
Beneficial conversion feature related to issuance and extension of convertible notes		(389,680	)
Derivative liabilities in connection with issuance and extension of convertible notes		(46,320	)
Balance of related notes payable, net as of March 31, 2022	$	104,025

Balance of related notes payable, net as of September 30, 2020	$	89,768
New convertible notes issued		190,000
Accrued Interest		10,392
Beneficial conversion feature related to issuance of convertible notes		(122,727	)
Balance of related notes payable, net as of March 31, 2021	$	167,433

Balance of non-related notes payable, net as of September 30, 2020	$	357,196
Accrued Interest		22,925
Balance of non-related notes payable, net as of March 31, 2021	$	380,121

Amendment

On December 31, 2021, all previously outstanding notes due December 31, 2021 were modified with amended expiry terms. The expiry of the notes was amended to December 31, 2023.

The Company determined that the extension of maturity dates resulted in extinguishment for Notes carrying interest at 12%, while the Notes carrying interest at 1% resulted in modification.

The Notes carrying interest at 1% did not have a change in cash flows greater than 10%, so these Notes were accounted for as a modification.

Embedded Derivative Liability

Beneficial Conversion Feature

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 20 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Mar. 31, 2022

RELATED PARTY TRANSACTIONS

6. RELATED PARTY TRANSACTIONS

The following is a summary of the related party transactions for the periods presented.

Eurema Consulting

As of March 31, 2022, and September 30, 2021, the balance due to Eurema Consulting S.r.l. was $0 and $200,000, respectively for past consultancy services.

Gabriele Cerrone

Roberto Pellicciari and TES Pharma

Tiziana Life Sciences Plc (“Tiziana”)

Panetta Partners

XML 21 R13.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Mar. 31, 2022

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

7. SUBSEQUENT EVENTS

XML 22 R14.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

6 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Basis of preparation

Basis of preparation

The results of the operations for the three and six months ended March 31, 2022 may not be indicative of the results that may be expected for the year ending September 30, 2022.

Principles of Consolidation

Principles of Consolidation

Use of Estimates

Use of Estimates

Net Income/(loss) per Share

Net Income/(loss) per Share

Diluted loss per share does not include any common stock equivalents as their effects are anti-dilutive.

The fully diluted earnings per share includes the shares issuable upon the conversion of the outstanding convertible loan notes for the three and six months to March 31, 2022.

	Three months March 31, 2022		Six months March 31, 2022
Net Income, numerator, basic computation		293,990		19,359
Interest expense		19,266		36,122
Net Income, numerator, diluted computation		313,256		55,481

Weighted average shares, denominator, basic computation		68,908,003		68,908,003
Effect of convertible notes		101,130,366		94,333,108
Weighted average shares, denominator, diluted computation		170,038,369		163,241,111

Earnings per share:
Basic		0.00		0.00
Diluted		0.00		0.00

The shares issuable on the exercise of options and warrants have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive.

	March 31, 2022		March 31, 2021
Stock options		3,648,675		3,648,675
Warrants		1,926,501		1,926,501
Convertible notes & associated fees		-		70,150,898
Total shares issuable upon exercise or conversion		5,575,176		75,726,074

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 23 R15.htm IDEA: XBRL DOCUMENT

Accounting Policies (Tables)

6 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Schedule of conversion of the outstanding convertible loan notes

	Three months March 31, 2022		Six months March 31, 2022
Net Income, numerator, basic computation		293,990		19,359
Interest expense		19,266		36,122
Net Income, numerator, diluted computation		313,256		55,481

Weighted average shares, denominator, basic computation		68,908,003		68,908,003
Effect of convertible notes		101,130,366		94,333,108
Weighted average shares, denominator, diluted computation		170,038,369		163,241,111

Earnings per share:
Basic		0.00		0.00
Diluted		0.00		0.00

Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants

	March 31, 2022		March 31, 2021
Stock options		3,648,675		3,648,675
Warrants		1,926,501		1,926,501
Convertible notes & associated fees		-		70,150,898
Total shares issuable upon exercise or conversion		5,575,176		75,726,074

XML 24 R16.htm IDEA: XBRL DOCUMENT

Convertible Notes (Tables)

6 Months Ended

Mar. 31, 2022

Convertible Notes [Abstract]

Schedule of convertible notes

Balance of non-related notes payable, net as of September 30, 2021	$	371,997
Accrued Interest		14,847
Accretion of debt discount		152,090
Beneficial conversion feature related to issuance and extension of convertible notes		(206,801	)
Derivative liabilities in connection with issuance and extension of convertible notes		(28,200	)
Balance of non-related notes payable, net as of March 31, 2022	$	303,933

Balance of related party notes payable, net as of September 30, 2021	$	230,287
Issuance of debt		160,000
Accrued Interest		21,275
Accretion of debt discount		128,463
Beneficial conversion feature related to issuance and extension of convertible notes		(389,680	)
Derivative liabilities in connection with issuance and extension of convertible notes		(46,320	)
Balance of related notes payable, net as of March 31, 2022	$	104,025

Balance of related notes payable, net as of September 30, 2020	$	89,768
New convertible notes issued		190,000
Accrued Interest		10,392
Beneficial conversion feature related to issuance of convertible notes		(122,727	)
Balance of related notes payable, net as of March 31, 2021	$	167,433

Balance of non-related notes payable, net as of September 30, 2020	$	357,196
Accrued Interest		22,925
Balance of non-related notes payable, net as of March 31, 2021	$	380,121

XML 25 R17.htm IDEA: XBRL DOCUMENT

Accounting Policies (Details) - Schedule of conversion of the outstanding convertible loan notes - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Schedule of conversion of the outstanding convertible loan notes [Abstract]
Net Income, numerator, basic computation	$ 293,990		$ 19,359
Interest expense	19,266		36,122
Net Income, numerator, diluted computation	$ 313,256		$ 55,481
Weighted average shares, denominator, basic computation	68,908,003		68,908,003
Effect of convertible notes	101,130,366		94,333,108
Weighted average shares, denominator, diluted computation	170,038,369		163,241,111
Earnings per share:
Basic	$ 0	$ 0	$ 0	$ (0.01)
Diluted	$ 0	$ 0	$ 0	$ (0.01)

XML 26 R18.htm IDEA: XBRL DOCUMENT

Accounting Policies (Details) - Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants - shares	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares issuable upon exercise or conversion	5,575,176	75,726,074
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares issuable upon exercise or conversion	1,926,501	1,926,501
Stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares issuable upon exercise or conversion	3,648,675	3,648,675
Convertible notes & associated fees [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares issuable upon exercise or conversion		70,150,898

XML 27 R19.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern (Details) - Liquidity and Going Concern [Member] - USD ($)	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Liquidity and Going Concern (Details) [Line Items]
Accumulated deficit		$ 23,515,120
Net income	$ (19,359)
Net cash used in operating activities	$ 142,770

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

+ Details

XML 28 R20.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details) - USD ($)	3 Months Ended	6 Months Ended
Share-Based Compensation (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2021
Share-Based Payment Arrangement [Abstract]
Share based compensation to directors	$ 17,796
Share based compensation to employees		$ 35,988

XML 29 R21.htm IDEA: XBRL DOCUMENT

Convertible Notes (Details) - USD ($)			1 Months Ended		3 Months Ended			6 Months Ended
Convertible Notes (Details) - USD ($)	Mar. 02, 2022	Feb. 08, 2022	Nov. 29, 2021	Nov. 18, 2021	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Convertible Notes (Details) [Line Items]
Percentage of convertible promissory note	16.00%	16.00%	12.00%	12.00%
Maturity date								Dec. 31, 2023
Cash	$ 45,000	$ 30,000		$ 30,000
Expiry date								Dec. 31, 2023
Carrying interest rate					1.00%			1.00%
Convertible notes description								The Company measured the present value of future cash flows that existed just prior to the earliest restructuring in the twelve-month period, which was used to apply the 10% test, since the earlier restructurings was accounted for as a modification. As the change in cash flows for all Notes carrying interest at 12% was greater than 10%, the term amendment was accounted for as an extinguishment. Under extinguishment accounting, the debt was remeasured and recorded at fair value. There was no difference between the carrying value of the debt, prior to the extinguishment, and the new fair value of the debt. The Notes carrying interest at 1% did not have a change in cash flows greater than 10%, so these Notes were accounted for as a modification
Interest rate						6.00%
Recognized an additional							$ 3,000		$ 71,520
Conversion of stock description		The Note provides the Holder with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price equal to the lower of (i) $0.005 per share or (ii) the price of the next equity financing, which raises at least US $1,000,000, subject to adjustments noted within the Agreement.
Convertible Promissory Note				(i) $0.01 per share or (ii) the price of the next equity financing, which raises at least US $1,000,000, subject to adjustments noted within the Agreement. The number of shares issuable upon a conversion shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of the Note to be converted by (y) the Conversion Price.
Convertible Debt [Member]
Convertible Notes (Details) [Line Items]
Cash			$ 55,000
Carrying interest rate					12.00%			12.00%
Recognized an additional					$ 10,114			$ 38,969
Beneficial Conversion Feature [Member]
Convertible Notes (Details) [Line Items]
Notes issued						$ 596,481

XML 30 R22.htm IDEA: XBRL DOCUMENT

Convertible Notes (Details) - Schedule of convertible notes - USD ($)	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Non-related notes payable [Member]
Convertible Notes (Details) - Schedule of convertible notes [Line Items]
Beginning balance	$ 371,997	$ 357,196
Ending balance	303,933	380,121
Accrued Interest	14,847	22,925
Accretion of debt discount	152,090
Beneficial conversion feature related to issuance and extension of convertible notes	(206,801)
Derivative liabilities in connection with issuance and extension of convertible notes	(28,200)
Related party notes payable [Member]
Convertible Notes (Details) - Schedule of convertible notes [Line Items]
Beginning balance	230,287	89,768
Ending balance	104,025	167,433
Issuance of debt	160,000
New convertible notes issued		190,000
Accrued Interest	21,275	10,392
Accretion of debt discount	128,463
Beneficial conversion feature related to issuance and extension of convertible notes	(389,680)	$ (122,727)
Derivative liabilities in connection with issuance and extension of convertible notes	$ (46,320)

XML 31 R23.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
Related Party Transactions (Details) - USD ($)	Sep. 30, 2021	Apr. 30, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2022
Related Party Transactions (Details) [Line Items]
Affiliates amount					$ 200,000
Royalties future percentage					20.00%
Balance due to Eurema consulting services	$ 200,000				$ 0
Balance due to related party					175,000
Loan facility amount		$ 7,000			83,520
Loan facility amount		$ 72,000
Interest expense			$ 1,440		2,880
Debt discounts net					358,817
Gabriele Cerrone [Member]
Related Party Transactions (Details) [Line Items]
Due to related party	175,000				$ 175,000
Convertible promissory notes, description				the Company entered into a 12% Convertible Promissory Note with Gabriele Cerrone for $20,000 with an extended maturity date of December 31, 2023. In February 2021, Gabriele Cerrone assigned the Note to Panetta Partners Ltd. In November 2021, the Company entered into two 12% Convertible Promissory Notes with Panetta Partners Ltd for the aggregate amount of $85,000. In February and March 2022, the Company entered into a further two 16% Convertible Promissory Notes with Panetta Partners Ltd for the $30,000 and $45,000 respectively.
Roberto Pellicciari and TES Pharma [Member]
Related Party Transactions (Details) [Line Items]
Royalties future percentage					20.00%
Accounts payable					$ 150,000
Balance due to related party	175,000				0
Company owed	75,000				0
Tiziana Life Sciences PLC [Member]
Related Party Transactions (Details) [Line Items]
Service charges					$ 25,822
Principal and accrued interest amount				$ 65,000
Interest charge, percentage					8.00%
Panetta Partners [Member]
Related Party Transactions (Details) [Line Items]
Principal and accrued interest amount					$ 462,842
Interest charge, percentage					12.00%
Total interest charge					$ 361,000
Notes issued	$ 276,303

XML 32 R24.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details)	May 13, 2022 shares
Forecast [Member]
Subsequent Events (Details) [Line Items]
Common stock shares issued	111,071,358

XML 33 f10q0322_rasnatherap_htm.xml IDEA: XBRL DOCUMENT 0001582249 2021-10-01 2022-03-31 0001582249 2022-06-16 0001582249 2022-03-31 0001582249 2021-09-30 0001582249 2022-01-01 2022-03-31 0001582249 2021-01-01 2021-03-31 0001582249 2020-10-01 2021-03-31 0001582249 us-gaap:CommonStockMember 2021-12-31 0001582249 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001582249 us-gaap:RetainedEarningsUnappropriatedMember 2021-12-31 0001582249 2021-12-31 0001582249 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001582249 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001582249 us-gaap:RetainedEarningsUnappropriatedMember 2022-01-01 2022-03-31 0001582249 us-gaap:CommonStockMember 2022-03-31 0001582249 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001582249 us-gaap:RetainedEarningsUnappropriatedMember 2022-03-31 0001582249 us-gaap:CommonStockMember 2020-12-31 0001582249 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001582249 us-gaap:RetainedEarningsUnappropriatedMember 2020-12-31 0001582249 2020-12-31 0001582249 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001582249 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001582249 us-gaap:RetainedEarningsUnappropriatedMember 2021-01-01 2021-03-31 0001582249 us-gaap:CommonStockMember 2021-03-31 0001582249 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001582249 us-gaap:RetainedEarningsUnappropriatedMember 2021-03-31 0001582249 2021-03-31 0001582249 us-gaap:CommonStockMember 2021-09-30 0001582249 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001582249 us-gaap:RetainedEarningsUnappropriatedMember 2021-09-30 0001582249 us-gaap:CommonStockMember 2021-10-01 2022-03-31 0001582249 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2022-03-31 0001582249 us-gaap:RetainedEarningsUnappropriatedMember 2021-10-01 2022-03-31 0001582249 us-gaap:CommonStockMember 2020-09-30 0001582249 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001582249 us-gaap:RetainedEarningsUnappropriatedMember 2020-09-30 0001582249 2020-09-30 0001582249 us-gaap:CommonStockMember 2020-10-01 2021-03-31 0001582249 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2021-03-31 0001582249 us-gaap:RetainedEarningsUnappropriatedMember 2020-10-01 2021-03-31 0001582249 us-gaap:EmployeeStockMember 2021-10-01 2022-03-31 0001582249 us-gaap:EmployeeStockMember 2020-10-01 2021-03-31 0001582249 us-gaap:WarrantMember 2021-10-01 2022-03-31 0001582249 us-gaap:WarrantMember 2020-10-01 2021-03-31 0001582249 rasp:ConvertibleNotesAssociatedFeesMember 2021-10-01 2022-03-31 0001582249 rasp:ConvertibleNotesAssociatedFeesMember 2020-10-01 2021-03-31 0001582249 rasp:LiquidityAndGoingConcernMember 2021-03-31 0001582249 rasp:LiquidityAndGoingConcernMember 2021-10-01 2022-03-31 0001582249 2021-11-01 2021-11-18 0001582249 2021-11-01 2021-11-29 0001582249 us-gaap:ConvertibleDebtMember 2021-11-01 2021-11-29 0001582249 2022-02-01 2022-02-08 0001582249 2022-03-01 2022-03-02 0001582249 us-gaap:ConvertibleDebtMember 2022-03-31 0001582249 us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0001582249 us-gaap:ConvertibleDebtMember 2021-10-01 2022-03-31 0001582249 rasp:BeneficialConversionFeatureMember 2021-10-01 2021-12-31 0001582249 rasp:NonRelatedPartyNotesPayableMember 2021-09-30 0001582249 rasp:NonRelatedPartyNotesPayableMember 2021-10-01 2022-03-31 0001582249 rasp:NonRelatedPartyNotesPayableMember 2022-03-31 0001582249 rasp:RelatedPartyNotesPayableMember 2021-09-30 0001582249 rasp:RelatedPartyNotesPayableMember 2021-10-01 2022-03-31 0001582249 rasp:RelatedPartyNotesPayableMember 2022-03-31 0001582249 rasp:RelatedPartyNotesPayableMember 2020-09-30 0001582249 rasp:RelatedPartyNotesPayableMember 2020-10-01 2021-03-31 0001582249 rasp:RelatedPartyNotesPayableMember 2021-03-31 0001582249 rasp:NonRelatedPartyNotesPayableMember 2020-09-30 0001582249 rasp:NonRelatedPartyNotesPayableMember 2020-10-01 2021-03-31 0001582249 rasp:NonRelatedPartyNotesPayableMember 2021-03-31 0001582249 rasp:GabrieleCerroneMember 2022-03-31 0001582249 rasp:GabrieleCerroneMember 2021-09-30 0001582249 rasp:GabrieleCerroneMember 2020-01-01 2020-03-31 0001582249 rasp:RobertoPellicciariAndTESPharmaMember 2022-03-31 0001582249 rasp:RobertoPellicciariAndTESPharmaMember 2021-10-01 2022-03-31 0001582249 rasp:RobertoPellicciariAndTESPharmaMember 2021-09-30 0001582249 rasp:RobertoPellicciariAndTESPharmaMember 2021-09-01 2021-09-30 0001582249 rasp:TizianaLifeSciencesPlcMember 2021-10-01 2022-03-31 0001582249 rasp:TizianaLifeSciencesPlcMember 2020-03-31 0001582249 rasp:TizianaLifeSciencesPlcMember 2022-03-31 0001582249 2020-04-30 0001582249 2020-04-01 2020-04-30 0001582249 rasp:PanettaPartnersMember 2022-03-31 0001582249 rasp:PanettaPartnersMember 2021-09-01 2021-09-30 0001582249 pf0:ScenarioForecastMember 2022-05-13 shares iso4217:USD iso4217:USD shares pure 10-Q true 2022-03-31 2022 false 333-191083 NV 39-2080103 420 Lexington Ave Suite 2525 New York NY 10170 (646) 396-4087 Yes Yes Non-accelerated Filer true false false 179979361

28078

10848

7620

33729

35698

44577

1407802

1516001

200822

561446

83520

80640

104025 230287

303933

371997

73569

38018

2173671

2798389

0.001

200000000

68908003

68909

21308238

20711758

-23515120

-23534479

-2137973

-2753812

35698

44577

126041

77555

198697

203824

17224

16067

26359

44739

150000

375000 375000

-381735

93622

-299944

248563

381735

-93622

299944

-248563

77153

27273

280553

27273

-123718 -123718 -20706 -21640 -39001 -38716 10114 38969 -107 48

-87745

-172738

-280585

-189659

293990

-266360

19359

-438222

293990

-266360

19359

-438222

-0.01

68908003

170038369

68908003

163241111

68908003

68909

21236238

-23809110

-2503963

72000

293990

68908003

68909

21308238

-23515120

-2137973

68908003

68909

19933076

-22830343

-2828358

17796

273718

-266360

68908003

68909

20224590

-23096703

-2803204

68908003

68909

20711758

-23534479

-2753812

596480

19359

68908003

68909

21308238

-23515120

-2137973

68908003

68909

19914884

-22658481

-2674688

35988

273718

-438222

68908003

68909

20224590

-23096703

-2803204

19359

-438222

35988

314

39002

2880

280553

27273

-38969

123718

150000

375000

41801

105613

14376

13413

-26108

43762

-748

-142770

-172037

160000

190000

17230

17963

10848

14241

28078

32204

74520 596481

1. GENERAL INFORMATION Rasna Therapeutics, Inc. “Rasna Inc.” or the “Company”), is a biotechnology company incorporated in the State of Delaware on March 28, 2016. The Company is engaged in modulating the molecular targets NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. These unaudited condensed consolidated financial statements are presented in United States dollars (“USD”) which is also the functional currency of the primary economic environment in which the Company operates. Risks and Uncertainties Management continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or ability to secure additional cash resources, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

2. ACCOUNTING POLICIES The principal accounting policies applied in the preparation of these unaudited condensed consolidated financial statements are set out below. These policies have been applied consistently to all the periods presented unless otherwise stated. There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s annual report on Form 10-K/A for the year ended September 30, 2021. Basis of preparation These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (the “SEC”) and United States generally accepted accounting principles (“US GAAP”) for interim reporting. The principles for condensed interim financial information do not require the inclusion of all the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements as of and for the year ended September 30, 2021 and notes thereto included in the Company’s Annual Report on Form 10-K/A filed with the SEC on June 9, 2022. The accompanying unaudited condensed consolidated financial statements have not been audited by an independent registered public accounting firm in accordance with the standards of the Public Company Accounting Oversight Board (United States), but in the opinion of management, such financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The results of the operations for the three and six months ended March 31, 2022 may not be indicative of the results that may be expected for the year ending September 30, 2022. Principles of Consolidation The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, Rasna Research Inc, and Rasna Research Inc’s subsidiary, Arna Therapeutics Limited. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to the fair values of share based awards, income taxes and contingent liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates and such differences could be material to the Company’s consolidated financial position and results of operations. Net Income/(loss) per Share Basic net income/(loss) per share is computed by dividing net income/(loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted income per share includes potentially dilutive securities such as outstanding options, warrants and convertible loan notes, using various methods such as the treasury stock, modified treasury stock, and if converted methods in the determination of dilutive shares outstanding during each reporting period. Common stock equivalents are included in the diluted income per share calculation only when exercise or conversion prices are lower than the average market price of the common shares for the periods presented. This does not apply to the diluted loss per share calculation. Diluted loss per share does not include any common stock equivalents as their effects are anti-dilutive. The fully diluted earnings per share includes the shares issuable upon the conversion of the outstanding convertible loan notes for the three and six months to March 31, 2022. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months March 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months March 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net Income, numerator, basic computation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">293,990</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">19,359</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Interest expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,266</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,122</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net Income, numerator, diluted computation</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">313,256</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">55,481</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, denominator, basic computation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,908,003</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,908,003</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Effect of convertible notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,130,366</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">94,333,108</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Weighted average shares, denominator, diluted computation</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">170,038,369</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">163,241,111</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Basic</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Diluted</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The shares issuable on the exercise of options and warrants have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,648,675</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,648,675</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,926,501</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,926,501</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible notes & associated fees</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,150,898</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total shares issuable upon exercise or conversion</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,575,176</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">75,726,074</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company does not intend to early adopt and continues to evaluate the impact of the provisions of ASU 2020-06 on its consolidated financial statements. The Company has determined that all other recently issued accounting pronouncements will not have a material impact on its consolidated financial position, results of operations and cash flows, or do not apply to its operations.

Basis of preparation These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (the “SEC”) and United States generally accepted accounting principles (“US GAAP”) for interim reporting. The principles for condensed interim financial information do not require the inclusion of all the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements as of and for the year ended September 30, 2021 and notes thereto included in the Company’s Annual Report on Form 10-K/A filed with the SEC on June 9, 2022. The accompanying unaudited condensed consolidated financial statements have not been audited by an independent registered public accounting firm in accordance with the standards of the Public Company Accounting Oversight Board (United States), but in the opinion of management, such financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The results of the operations for the three and six months ended March 31, 2022 may not be indicative of the results that may be expected for the year ending September 30, 2022.

Principles of Consolidation The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiary, Rasna Research Inc, and Rasna Research Inc’s subsidiary, Arna Therapeutics Limited. All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements.

Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to the fair values of share based awards, income taxes and contingent liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates and such differences could be material to the Company’s consolidated financial position and results of operations.

Net Income/(loss) per Share Basic net income/(loss) per share is computed by dividing net income/(loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted income per share includes potentially dilutive securities such as outstanding options, warrants and convertible loan notes, using various methods such as the treasury stock, modified treasury stock, and if converted methods in the determination of dilutive shares outstanding during each reporting period. Common stock equivalents are included in the diluted income per share calculation only when exercise or conversion prices are lower than the average market price of the common shares for the periods presented. This does not apply to the diluted loss per share calculation. Diluted loss per share does not include any common stock equivalents as their effects are anti-dilutive. The fully diluted earnings per share includes the shares issuable upon the conversion of the outstanding convertible loan notes for the three and six months to March 31, 2022. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months March 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months March 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net Income, numerator, basic computation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">293,990</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">19,359</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Interest expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,266</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,122</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net Income, numerator, diluted computation</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">313,256</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">55,481</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, denominator, basic computation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,908,003</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,908,003</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Effect of convertible notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,130,366</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">94,333,108</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Weighted average shares, denominator, diluted computation</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">170,038,369</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">163,241,111</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Basic</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Diluted</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The shares issuable on the exercise of options and warrants have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,648,675</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,648,675</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,926,501</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,926,501</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible notes & associated fees</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,150,898</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total shares issuable upon exercise or conversion</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,575,176</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">75,726,074</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months March 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months March 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net Income, numerator, basic computation</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">293,990</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">19,359</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Interest expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,266</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,122</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net Income, numerator, diluted computation</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">313,256</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">55,481</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, denominator, basic computation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,908,003</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,908,003</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Effect of convertible notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,130,366</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">94,333,108</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Weighted average shares, denominator, diluted computation</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">170,038,369</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">163,241,111</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Basic</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Diluted</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.00</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

293990

19359

19266

36122

313256

55481

68908003

101130366 94333108

170038369

163241111

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Stock options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,648,675</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3,648,675</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,926,501</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,926,501</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Convertible notes & associated fees</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,150,898</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Total shares issuable upon exercise or conversion</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,575,176</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">75,726,074</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

3648675

1926501

70150898

5575176

75726074

Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company does not intend to early adopt and continues to evaluate the impact of the provisions of ASU 2020-06 on its consolidated financial statements. The Company has determined that all other recently issued accounting pronouncements will not have a material impact on its consolidated financial position, results of operations and cash flows, or do not apply to its operations.

3. LIQUIDITY AND GOING CONCERN The Company has no present revenue and has experienced net losses and significant cash outflows from cash used in operating activities since inception. The Company is subject to a number of risks similar to those of other pre-commercial stage companies, including its dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with research, development, testing, and obtaining related regulatory approvals of its pipeline products, suppliers and collaborators, successful protection of intellectual property, competition with larger, better-capitalized companies, successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including obtaining adequate financing to fulfill its development activities and generating a level of revenues adequate to support the Company’s cost structure. The Company has generally experienced net losses and significant cash outflows from cash used in operating activities over the past two years, and as of March 31, 2021, had an accumulated deficit of $23,515,120, a net income for the six months March 31, 2022 of $19,359 and net cash used in operating activities of $142,770. The Company expects to continue to incur net losses and have significant cash outflows for at least the next 12 months and will require significant additional cash resources to launch new development phases of existing products in its pipeline. In the event that the Company is unable to secure the additional cash resources needed, the Company may slow current development phases or halt new development phases in order to mitigate the effects of the costs of development. These conditions, among others, raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern one year from the date of this filing. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support the Company’s cost structure.

23515120

-19359

142770

4. SHARE-BASED COMPENSATION For the three and six months ended March 31, 2022 there have been no charges for share based compensation. For the three and six months ended March 31, 2021, $17,796 and $35,988 related to share based compensation to directors and employees respectively, has been included within the general and administrative expense category in the accompanying unaudited condensed consolidated interim financial statements.

17796

35988

5. CONVERTIBLE NOTES The table below summarizes outstanding convertible notes as of March 31, 2022 and March 31, 2021: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; font-weight: bold">Balance of non-related notes payable, net as of September 30, 2021</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">371,997</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,847</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accretion of debt discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">152,090</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Beneficial conversion feature related to issuance and extension of convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(206,801</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Derivative liabilities in connection with issuance and extension of convertible notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,200</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Balance of non-related notes payable, net as of March 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">303,933</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance of related party notes payable, net as of September 30, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">230,287</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Issuance of debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,275</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accretion of debt discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,463</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Beneficial conversion feature related to issuance and extension of convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(389,680</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Derivative liabilities in connection with issuance and extension of convertible notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(46,320</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance of related notes payable, net as of March 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">104,025</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Balance of related notes payable, net as of September 30, 2020</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">89,768</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">New convertible notes issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">190,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,392</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Beneficial conversion feature related to issuance of convertible notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(122,727</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Balance of related notes payable, net as of March 31, 2021</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">167,433</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Balance of non-related notes payable, net as of September 30, 2020</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">357,196</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued Interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,925</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Balance of non-related notes payable, net as of March 31, 2021</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">380,121</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> On November 18, 2021, the Company entered into an eleventh 12% Convertible Promissory Note with Panetta Partners Ltd. (the “Holder”) with a maturity date of December 31, 2023. The Holder provided the Company with $30,000 in cash. The Note provides the Holder with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price equal to the lower of (i) $0.01 per share or (ii) the price of the next equity financing, which raises at least US $1,000,000, subject to adjustments noted within the Agreement. The number of shares issuable upon a conversion shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of the Note to be converted by (y) the Conversion Price. The Note requires the Company to reserve and keep available out of its authorized and unissued shares of common stock the amount of shares that would be issued upon conversion of the Note, which includes the outstanding principal amount of the Note and interest accrued and to be accrued through the date of maturity. On November 29, 2021, the Company entered into the twelfth 12% Convertible Promissory Note again with Panetta Partners Ltd. (the “Holder”) pursuant to which the Company issued a Convertible Promissory Note to the Holder. The Holder provided the Company with $55,000 in cash. All other terms were the same as the eleventh note. On February 8, 2022, the Company entered into the thirteenth 16% Convertible Promissory Note again with Panetta Partners Ltd. (the “Holder”) pursuant to which the Company issued a Convertible Promissory Note to the Holder. The Holder provided the Company with $30,000 in cash. The Note provides the Holder with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price equal to the lower of (i) $0.005 per share or (ii) the price of the next equity financing, which raises at least US $1,000,000, subject to adjustments noted within the Agreement. The number of shares issuable upon a conversion shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of the Note to be converted by (y) the Conversion Price. The Note requires the Company to reserve and keep available out of its authorized and unissued shares of common stock the amount of shares that would be issued upon conversion of the Note, which includes the outstanding principal amount of the Note and interest accrued and to be accrued through the date of maturity. On March 2, 2022, the Company entered into the fourteenth 16% Convertible Promissory Note again with Panetta Partners Ltd. (the “Holder”) pursuant to which the Company issued a Convertible Promissory Note to the Holder. The Holder provided the Company with $45,000 in cash. All other terms were the same as the thirteenth note. Amendment On December 31, 2021, all previously outstanding notes due December 31, 2021 were modified with amended expiry terms. The expiry of the notes was amended to December 31, 2023. The Company determined that the extension of maturity dates resulted in extinguishment for Notes carrying interest at 12%, while the Notes carrying interest at 1% resulted in modification. The Company measured the present value of future cash flows that existed just prior to the earliest restructuring in the twelve-month period, which was used to apply the 10% test, since the earlier restructurings was accounted for as a modification. As the change in cash flows for all Notes carrying interest at 12% was greater than 10%, the term amendment was accounted for as an extinguishment. Under extinguishment accounting, the debt was remeasured and recorded at fair value. There was no difference between the carrying value of the debt, prior to the extinguishment, and the new fair value of the debt. The Notes carrying interest at 1% did not have a change in cash flows greater than 10%, so these Notes were accounted for as a modification. The Company also noted that the stock was thinly traded with any trading activity resulting in a disproportionate effect on the stock price. Therefore, a Black Scholes valuation was deemed to be inappropriate in this case. Embedded Derivative Liability Under the promissory note agreement, the interest rate will reset upon the event of a default and an additional penalty of 6% will be accrued. The Company analyzed the conversion features of the note agreement for derivative accounting consideration under ASC 815, Derivatives and Hedging, and determined the interest rate resets met the definition of a derivative. It also noted that the Contingent Interest Rate feature required bifurcation from the host note contract and was to be accounted for at fair value. In accordance with ASC 815-15, the Company bifurcated the Contingent Interest Rate feature of the note and recorded a derivative liability. The embedded derivatives for the notes are carried on the Company’s balance sheet at fair value. During the three and six months to March 31, 2021, the Company recognized an additional $3,000 and $71,520 respectively due to the extension and issuance of the convertible notes. Additionally, the Company recognized a gain of $10,114 and $38,969 for the three and six month periods ended March 31, 2022, relating to the issuance and extension of convertible notes. Beneficial Conversion Feature The conversion features for all notes issued are in the money as of the issuance date and accordingly a beneficial conversion feature was recorded upon issuance. As the intrinsic value of the Beneficial Conversion Feature exceeds the face value, the recorded Beneficial Conversion Feature will be limited to the gross proceeds less any debt discounts. As at March 31, 2022 this amounted to $596,481 for the amended and new notes issued.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; font-weight: bold">Balance of non-related notes payable, net as of September 30, 2021</td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 9%; font-weight: bold; text-align: right">371,997</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,847</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accretion of debt discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">152,090</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Beneficial conversion feature related to issuance and extension of convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(206,801</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Derivative liabilities in connection with issuance and extension of convertible notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,200</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Balance of non-related notes payable, net as of March 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">303,933</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance of related party notes payable, net as of September 30, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">230,287</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Issuance of debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accrued Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,275</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Accretion of debt discount</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,463</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Beneficial conversion feature related to issuance and extension of convertible notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(389,680</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Derivative liabilities in connection with issuance and extension of convertible notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(46,320</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance of related notes payable, net as of March 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">104,025</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Balance of related notes payable, net as of September 30, 2020</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">89,768</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">New convertible notes issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">190,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Accrued Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,392</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Beneficial conversion feature related to issuance of convertible notes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(122,727</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Balance of related notes payable, net as of March 31, 2021</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">167,433</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Balance of non-related notes payable, net as of September 30, 2020</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">357,196</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued Interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,925</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt">Balance of non-related notes payable, net as of March 31, 2021</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">380,121</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

371997

14847

152090

-206801

-28200

303933

230287

160000

21275

128463

-389680

-46320

104025

89768

190000

10392

-122727

167433

357196

22925

380121 0.12

2023-12-31

30000

(i) $0.01 per share or (ii) the price of the next equity financing, which raises at least US $1,000,000, subject to adjustments noted within the Agreement. The number of shares issuable upon a conversion shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of the Note to be converted by (y) the Conversion Price. 0.12

55000

0.16

30000

The Note provides the Holder with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price equal to the lower of (i) $0.005 per share or (ii) the price of the next equity financing, which raises at least US $1,000,000, subject to adjustments noted within the Agreement.

0.16

45000

2023-12-31

0.12

0.01

0.06

3000

71520

10114

38969

596481

6. RELATED PARTY TRANSACTIONS The following is a summary of the related party transactions for the periods presented. Eurema Consulting Eurema Consulting S.r.l. is a significant shareholder of the Company. During the three and six months ended March 31, 2022 and March 31, 2021 Eurema Consulting did not supply the Company with consulting services. In March 2022, the Company agreed to return back to Eurema Consulting S.R.L all intellectual property rights and assignments relating to NPM1. In exchange for this, Eurema Consulting S.R.L agreed to waive any payments due to them and their affiliates by Rasna, this amounted to a $200,000 gain on the settlement of the related party payable. Rasna may be entitled to 20% of any future royalties and/or milestone payments upon successful completion of a clinical Proof of Concept study under certain agreed upon circumstances. As of March 31, 2022, and September 30, 2021, the balance due to Eurema Consulting S.r.l. was $0 and $200,000, respectively for past consultancy services. Gabriele Cerrone Gabriele Cerrone is the majority shareholder of Panetta Partners, one of the Company’s principal shareholders. As of March 31, 2022, and September 30, 2021, the balance due to Gabriele Cerrone was $175,000 for past consultancy services. In March 2020, the Company entered into a 12% Convertible Promissory Note with Gabriele Cerrone for $20,000 with an extended maturity date of December 31, 2023. In February 2021, Gabriele Cerrone assigned the Note to Panetta Partners Ltd. In November 2021, the Company entered into two 12% Convertible Promissory Notes with Panetta Partners Ltd for the aggregate amount of $85,000. In February and March 2022, the Company entered into a further two 16% Convertible Promissory Notes with Panetta Partners Ltd for the $30,000 and $45,000 respectively. Roberto Pellicciari and TES Pharma Roberto Pellicciari is the majority shareholder of TES Pharma Srl, one of the Company’s principal shareholders. During the three and six months ended March 31, 2022 and March 31, 2021, Roberto Pellicciari did not supply the Company with consulting services. In March 2022, the Company agreed to return back to TES Pharma S.R.L all intellectual property rights and assignments relating to NPM1. In exchange for this, TES Pharma S.R.L agreed to waive any payments due to them and their affiliates (which includes Roberto Pelliciari) by Rasna. this amounted to a $175,000 gain on the settlement of the related party payable to Roberto Pellicciari and a $150,000 gain on the settlement of accounts payable to TES Pharma and its affiliates. Rasna may be entitled to 20% of any future royalties and/or milestone payments upon successful completion of a clinical Proof of Concept study under certain agreed upon circumstances. As of March 31, 2022, and September 30, 2021, the balance due to Roberto Pellicciari was $0 and $175,000 respectively, for past consultancy services. At March 31, 2022 and September 30, 2021, TES Pharma was owed $0 and $75,000 respectively. Tiziana Life Sciences Plc (“Tiziana”) The Company is party to a Shared Services Agreement with Tiziana, whereby the Company is charged for shared services and rent. Tiziana had previously agreed to waive all charges for shared services from October 2018 onwards, until further notice since the amounts due for such services are de minimis. Notice was given and recharges from October 1, 2020 were resumed. Keeren Shah, the Company’s Finance Director, is also Finance Director of Tiziana, and the Company’s directors, Willy Simon and John Brancaccio are also non-executive directors of Tiziana. As of March 31, 2022, $25,822 was due to Tiziana under services charged under the shared services agreement. This is recorded as a related party payable in the accompanying condensed consolidated balance sheets. In March 2020, Tiziana extended a loan facility to Rasna of $65,000. The loan is repayable within 18 months and is incurring an interest charge of 8% per annum. In April 2020, the loan facility was extended by a further $7,000, so the loan facility totals $72,000. As of March 31, 2022, the amounts due to Tiziana under this loan facility were $83,520 and the interest charged in the three and six months to March 31, 2021, was $1,440 and $2,880 respectively. Panetta Partners Panetta Partners Limited, a shareholder of Rasna, is a company in which Gabriele Cerrone is a major shareholder and also serves as a director. The Company has entered into numerous 12% Convertible Promissory Notes with Panetta Partners for a total of $361,000. The amount due for these notes as at March 31, 2022, with respect to the principal and accrued interest is $462,842, net of debt discounts of $358,817 . As at September 30, 2021 $276,303 was due with respect to notes issued. Apart from the Convertible Promissory Notes, there is no interest charged on the balances with related parties. There are no defined repayment terms and such amounts can be called for payment at any time.

200000 0.20

200000

175000

the Company entered into a 12% Convertible Promissory Note with Gabriele Cerrone for $20,000 with an extended maturity date of December 31, 2023. In February 2021, Gabriele Cerrone assigned the Note to Panetta Partners Ltd. In November 2021, the Company entered into two 12% Convertible Promissory Notes with Panetta Partners Ltd for the aggregate amount of $85,000. In February and March 2022, the Company entered into a further two 16% Convertible Promissory Notes with Panetta Partners Ltd for the $30,000 and $45,000 respectively.

175000

150000

0.20

175000

0 75000

25822

65000

0.08

7000

72000

83520

1440

2880

0.12

361000

462842

358817

276303

7. SUBSEQUENT EVENTS On May 13, 2022, the Company received notice from all noteholders that all notes were to be converted into stock. The Company issued 111,071,358 of common stock on May 13, 2022 in respect of these conversions.

111071358

Rasna Therapeutics Inc.

false --09-30 Q2 0001582249

EXCEL 34 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 36 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 85 149 1 false 16 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.rasna.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.rasna.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://www.rasna.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.rasna.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Changes in Shareholders??? Equity/(Deficit) (Unaudited) Sheet http://www.rasna.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Changes in Shareholders??? Equity/(Deficit) (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.rasna.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - General Information Sheet http://www.rasna.com/role/GeneralInformation General Information Notes 7 false false R8.htm 007 - Disclosure - Accounting Policies Sheet http://www.rasna.com/role/AccountingPolicies Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Liquidity and Going Concern Sheet http://www.rasna.com/role/LiquidityandGoingConcern Liquidity and Going Concern Notes 9 false false R10.htm 009 - Disclosure - Share-Based Compensation Sheet http://www.rasna.com/role/ShareBasedCompensation Share-Based Compensation Notes 10 false false R11.htm 010 - Disclosure - Convertible Notes Notes http://www.rasna.com/role/ConvertibleNotes Convertible Notes Notes 11 false false R12.htm 011 - Disclosure - Related Party Transactions Sheet http://www.rasna.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 012 - Disclosure - Subsequent Events Sheet http://www.rasna.com/role/SubsequentEvents Subsequent Events Notes 13 false false R14.htm 013 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.rasna.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.rasna.com/role/AccountingPolicies 14 false false R15.htm 014 - Disclosure - Accounting Policies (Tables) Sheet http://www.rasna.com/role/AccountingPoliciesTables Accounting Policies (Tables) Tables http://www.rasna.com/role/AccountingPolicies 15 false false R16.htm 015 - Disclosure - Convertible Notes (Tables) Notes http://www.rasna.com/role/ConvertibleNotesTables Convertible Notes (Tables) Tables http://www.rasna.com/role/ConvertibleNotes 16 false false R17.htm 016 - Disclosure - Accounting Policies (Details) - Schedule of conversion of the outstanding convertible loan notes Notes http://www.rasna.com/role/ScheduleofconversionoftheoutstandingconvertibleloannotesTable Accounting Policies (Details) - Schedule of conversion of the outstanding convertible loan notes Details http://www.rasna.com/role/AccountingPoliciesTables 17 false false R18.htm 017 - Disclosure - Accounting Policies (Details) - Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants Sheet http://www.rasna.com/role/ScheduleofpotentialcommonsharesissuableupontheexerciseofoutstandingoptionsandtheexerciseofwarrantsTable Accounting Policies (Details) - Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants Details http://www.rasna.com/role/AccountingPoliciesTables 18 false false R19.htm 018 - Disclosure - Liquidity and Going Concern (Details) Sheet http://www.rasna.com/role/LiquidityandGoingConcernDetails Liquidity and Going Concern (Details) Details http://www.rasna.com/role/LiquidityandGoingConcern 19 false false R20.htm 019 - Disclosure - Share-Based Compensation (Details) Sheet http://www.rasna.com/role/ShareBasedCompensationDetails Share-Based Compensation (Details) Details http://www.rasna.com/role/ShareBasedCompensation 20 false false R21.htm 020 - Disclosure - Convertible Notes (Details) Notes http://www.rasna.com/role/ConvertibleNotesDetails Convertible Notes (Details) Details http://www.rasna.com/role/ConvertibleNotesTables 21 false false R22.htm 021 - Disclosure - Convertible Notes (Details) - Schedule of convertible notes Notes http://www.rasna.com/role/ScheduleofconvertiblenotesTable Convertible Notes (Details) - Schedule of convertible notes Details http://www.rasna.com/role/ConvertibleNotesTables 22 false false R23.htm 022 - Disclosure - Related Party Transactions (Details) Sheet http://www.rasna.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.rasna.com/role/RelatedPartyTransactions 23 false false R24.htm 023 - Disclosure - Subsequent Events (Details) Sheet http://www.rasna.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.rasna.com/role/SubsequentEvents 24 false false All Reports Book All Reports f10q0322_rasnatherap.htm f10q0322ex31-1_rasnatherap.htm f10q0322ex32-1_rasnatherap.htm rasp-20220331.xsd rasp-20220331_cal.xml rasp-20220331_def.xml rasp-20220331_lab.xml rasp-20220331_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 40 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0322_rasnatherap.htm": { "axisCustom": 0, "axisStandard": 7, "contextCount": 85, "dts": { "calculationLink": { "local": [ "rasp-20220331_cal.xml" ] }, "definitionLink": { "local": [ "rasp-20220331_def.xml" ] }, "inline": { "local": [ "f10q0322_rasnatherap.htm" ] }, "labelLink": { "local": [ "rasp-20220331_lab.xml" ] }, "presentationLink": { "local": [ "rasp-20220331_pre.xml" ] }, "schema": { "local": [ "rasp-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 219, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 33, "http://www.rasna.com/20220331": 4, "http://xbrl.sec.gov/dei/2022": 5, "total": 42 }, "keyCustom": 23, "keyStandard": 126, "memberCustom": 9, "memberStandard": 7, "nsprefix": "rasp", "nsuri": "http://www.rasna.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.rasna.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Share-Based Compensation", "role": "http://www.rasna.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Convertible Notes", "role": "http://www.rasna.com/role/ConvertibleNotes", "shortName": "Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Related Party Transactions", "role": "http://www.rasna.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Subsequent Events", "role": "http://www.rasna.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://www.rasna.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Accounting Policies (Tables)", "role": "http://www.rasna.com/role/AccountingPoliciesTables", "shortName": "Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Convertible Notes (Tables)", "role": "http://www.rasna.com/role/ConvertibleNotesTables", "shortName": "Convertible Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Accounting Policies (Details) - Schedule of conversion of the outstanding convertible loan notes", "role": "http://www.rasna.com/role/ScheduleofconversionoftheoutstandingconvertibleloannotesTable", "shortName": "Accounting Policies (Details) - Schedule of conversion of the outstanding convertible loan notes", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Accounting Policies (Details) - Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants", "role": "http://www.rasna.com/role/ScheduleofpotentialcommonsharesissuableupontheexerciseofoutstandingoptionsandtheexerciseofwarrantsTable", "shortName": "Accounting Policies (Details) - Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c47", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAppropriated", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Liquidity and Going Concern (Details)", "role": "http://www.rasna.com/role/LiquidityandGoingConcernDetails", "shortName": "Liquidity and Going Concern (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c47", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAppropriated", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.rasna.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c5", "decimals": "0", "first": true, "lang": null, "name": "rasp:DirectorsBenefitsAndShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Share-Based Compensation (Details)", "role": "http://www.rasna.com/role/ShareBasedCompensationDetails", "shortName": "Share-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c5", "decimals": "0", "first": true, "lang": null, "name": "rasp:DirectorsBenefitsAndShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c53", "decimals": "2", "first": true, "lang": null, "name": "rasp:ConvertiblePromissoryNote", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Convertible Notes (Details)", "role": "http://www.rasna.com/role/ConvertibleNotesDetails", "shortName": "Convertible Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c53", "decimals": "2", "first": true, "lang": null, "name": "rasp:ConvertiblePromissoryNote", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c58", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Convertible Notes (Details) - Schedule of convertible notes", "role": "http://www.rasna.com/role/ScheduleofconvertiblenotesTable", "shortName": "Convertible Notes (Details) - Schedule of convertible notes", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c58", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "rasp:AffiliatesAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Related Party Transactions (Details)", "role": "http://www.rasna.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "rasp:AffiliatesAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c84", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ExcessStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Subsequent Events (Details)", "role": "http://www.rasna.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c84", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ExcessStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c2", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "role": "http://www.rasna.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c2", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://www.rasna.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c34", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Changes in Shareholders\u2019 Equity/(Deficit) (Unaudited)", "role": "http://www.rasna.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Statements of Changes in Shareholders\u2019 Equity/(Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c34", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.rasna.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c6", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - General Information", "role": "http://www.rasna.com/role/GeneralInformation", "shortName": "General Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Accounting Policies", "role": "http://www.rasna.com/role/AccountingPolicies", "shortName": "Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Liquidity and Going Concern", "role": "http://www.rasna.com/role/LiquidityandGoingConcern", "shortName": "Liquidity and Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0322_rasnatherap.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 16, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.rasna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "rasp_AccretionOfDebtDiscount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accretion of debt discount.", "label": "AccretionOfDebtDiscount", "terseLabel": "Accretion of debt discount" } } }, "localname": "AccretionOfDebtDiscount", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "rasp_AffiliatesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "AffiliatesAmount", "terseLabel": "Affiliates amount" } } }, "localname": "AffiliatesAmount", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rasp_BeneficialConversionFeatureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BeneficialConversionFeatureMember", "terseLabel": "Beneficial Conversion Feature [Member]" } } }, "localname": "BeneficialConversionFeatureMember", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "rasp_BeneficialConversionFeatureRelatedToIssuanceOfConvertibleNotes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Beneficial conversion feature related to issuance of convertible notes.", "label": "BeneficialConversionFeatureRelatedToIssuanceOfConvertibleNotes", "terseLabel": "Beneficial conversion feature related to issuance and extension of convertible notes" } } }, "localname": "BeneficialConversionFeatureRelatedToIssuanceOfConvertibleNotes", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "rasp_CarryingValueOfNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying Value of Note.", "label": "CarryingValueOfNote", "periodEndLabel": "Ending balance" } } }, "localname": "CarryingValueOfNote", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "rasp_CompanyOwed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "CompanyOwed", "terseLabel": "Company owed" } } }, "localname": "CompanyOwed", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rasp_ConvertibleNotesAssociatedFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertibleNotesAssociatedFeesMember", "terseLabel": "Convertible notes & associated fees [Member]" } } }, "localname": "ConvertibleNotesAssociatedFeesMember", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ScheduleofpotentialcommonsharesissuableupontheexerciseofoutstandingoptionsandtheexerciseofwarrantsTable" ], "xbrltype": "domainItemType" }, "rasp_ConvertibleNotesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible notes description", "label": "ConvertibleNotesDescription", "terseLabel": "Convertible notes description" } } }, "localname": "ConvertibleNotesDescription", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "rasp_ConvertibleNotesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes (Details) [Line Items]" } } }, "localname": "ConvertibleNotesDetailsLineItems", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "rasp_ConvertibleNotesDetailsScheduleofconvertiblenotesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes (Details) - Schedule of convertible notes [Line Items]" } } }, "localname": "ConvertibleNotesDetailsScheduleofconvertiblenotesLineItems", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "stringItemType" }, "rasp_ConvertibleNotesDetailsScheduleofconvertiblenotesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes (Details) - Schedule of convertible notes [Table]" } } }, "localname": "ConvertibleNotesDetailsScheduleofconvertiblenotesTable", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "stringItemType" }, "rasp_ConvertibleNotesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes (Details) [Table]" } } }, "localname": "ConvertibleNotesDetailsTable", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "rasp_ConvertibleNotesPayableRelatedParty": { "auth_ref": [], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of Convertible notes payable - related party.", "label": "ConvertibleNotesPayableRelatedParty", "terseLabel": "Convertible notes payable, net - related party" } } }, "localname": "ConvertibleNotesPayableRelatedParty", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "rasp_ConvertiblePromissoryNote": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible promissory note.", "label": "ConvertiblePromissoryNote", "terseLabel": "Percentage of convertible promissory note" } } }, "localname": "ConvertiblePromissoryNote", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "rasp_ConvertiblePromissoryNoteDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertiblePromissoryNoteDescription", "terseLabel": "Convertible Promissory Note" } } }, "localname": "ConvertiblePromissoryNoteDescription", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "rasp_ConvertiblePromissoryNotesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertiblePromissoryNotesDescription", "terseLabel": "Convertible promissory notes, description" } } }, "localname": "ConvertiblePromissoryNotesDescription", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "rasp_DebtDiscounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Debt discounts", "label": "DebtDiscounts", "terseLabel": "Debt discounts net" } } }, "localname": "DebtDiscounts", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rasp_DebtExpiryDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiry date.", "label": "DebtExpiryDate", "terseLabel": "Expiry date" } } }, "localname": "DebtExpiryDate", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "dateItemType" }, "rasp_DerivativeLiabilitiesInConnectionWithDebtExtinguishments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of derivative liabilities in connection with debt extinguishments.", "label": "DerivativeLiabilitiesInConnectionWithDebtExtinguishments", "terseLabel": "Derivative liabilities in connection with issuance and extension of convertible notes" } } }, "localname": "DerivativeLiabilitiesInConnectionWithDebtExtinguishments", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "rasp_DirectorsBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of directors benefits and share based compensation.", "label": "DirectorsBenefitsAndShareBasedCompensation", "terseLabel": "Share based compensation to directors" } } }, "localname": "DirectorsBenefitsAndShareBasedCompensation", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "rasp_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.rasna.com/20220331", "xbrltype": "stringItemType" }, "rasp_EffectOfConvertibleNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effect of convertible shares.", "label": "EffectOfConvertibleNotes", "terseLabel": "Effect of convertible notes" } } }, "localname": "EffectOfConvertibleNotes", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ScheduleofconversionoftheoutstandingconvertibleloannotesTable" ], "xbrltype": "sharesItemType" }, "rasp_FeeForConvertibleLoanNoteToBeSettledInEquity": { "auth_ref": [], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fee for convertible loan note to be settled in equity.", "label": "FeeForConvertibleLoanNoteToBeSettledInEquity", "terseLabel": "Fee for convertible loan note to be settled in equity" } } }, "localname": "FeeForConvertibleLoanNoteToBeSettledInEquity", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "rasp_FeesDueOnPromissoryNotes": { "auth_ref": [], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fees due on promissory note", "label": "FeesDueOnPromissoryNotes", "terseLabel": "Expenses in connection with modification and extinguishment of convertible promissory notes" } } }, "localname": "FeesDueOnPromissoryNotes", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "rasp_ForeignCurrencyTransactionGainloss": { "auth_ref": [], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Foreign currency transaction gain/(loss)", "label": "ForeignCurrencyTransactionGainloss", "terseLabel": "Foreign currency transaction (loss)/gain" } } }, "localname": "ForeignCurrencyTransactionGainloss", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "rasp_GabrieleCerroneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GabrieleCerroneMember", "terseLabel": "Gabriele Cerrone [Member]" } } }, "localname": "GabrieleCerroneMember", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rasp_GainOnSettlementOfRelatedPartyPayable": { "auth_ref": [], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of gain on settlement of related party payable which is extinguished prior to maturity.", "label": "GainOnSettlementOfRelatedPartyPayable", "negatedLabel": "Gain on settlement of related party payable" } } }, "localname": "GainOnSettlementOfRelatedPartyPayable", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow", "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "rasp_GainOnTroubledDebtsRestructuring": { "auth_ref": [], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on troubled debt restructuring", "label": "GainOnTroubledDebtsRestructuring", "terseLabel": "Gain on derivative liability" } } }, "localname": "GainOnTroubledDebtsRestructuring", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "rasp_InterestOnConvertibleNotesPayable": { "auth_ref": [], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on convertible debt.", "label": "InterestOnConvertibleNotesPayable", "terseLabel": "Interest expense" } } }, "localname": "InterestOnConvertibleNotesPayable", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "rasp_LiquidityAndGoingConcernMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LiquidityAndGoingConcernMember", "terseLabel": "Liquidity and Going Concern [Member]" } } }, "localname": "LiquidityAndGoingConcernMember", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/LiquidityandGoingConcernDetails" ], "xbrltype": "domainItemType" }, "rasp_LiquidityandGoingConcernDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity and Going Concern (Details) [Line Items]" } } }, "localname": "LiquidityandGoingConcernDetailsLineItems", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/LiquidityandGoingConcernDetails" ], "xbrltype": "stringItemType" }, "rasp_LiquidityandGoingConcernDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity and Going Concern (Details) [Table]" } } }, "localname": "LiquidityandGoingConcernDetailsTable", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/LiquidityandGoingConcernDetails" ], "xbrltype": "stringItemType" }, "rasp_LoanFacilityTotal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "LoanFacilityTotal", "terseLabel": "Loan facility amount" } } }, "localname": "LoanFacilityTotal", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "rasp_NonRelatedPartyNotesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NonRelatedPartyNotesPayableMember", "terseLabel": "Non-related notes payable [Member]" } } }, "localname": "NonRelatedPartyNotesPayableMember", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "domainItemType" }, "rasp_PanettaPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PanettaPartnersMember", "terseLabel": "Panetta Partners [Member]" } } }, "localname": "PanettaPartnersMember", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rasp_RelatedPartyNotesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RelatedPartyNotesPayableMember", "terseLabel": "Related party notes payable [Member]" } } }, "localname": "RelatedPartyNotesPayableMember", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "domainItemType" }, "rasp_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "rasp_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "rasp_RobertoPellicciariAndTESPharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RobertoPellicciariAndTESPharmaMember", "terseLabel": "Roberto Pellicciari and TES Pharma [Member]" } } }, "localname": "RobertoPellicciariAndTESPharmaMember", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "rasp_RoyaltiesFuturePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RoyaltiesFuturePercentage", "terseLabel": "Royalties future percentage" } } }, "localname": "RoyaltiesFuturePercentage", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "rasp_ScheduleOfConversionOfTheOutstandingConvertibleLoanNotesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of conversion of the outstanding convertible loan notes [Abstract]" } } }, "localname": "ScheduleOfConversionOfTheOutstandingConvertibleLoanNotesAbstract", "nsuri": "http://www.rasna.com/20220331", "xbrltype": "stringItemType" }, "rasp_ScheduleOfConvertibleNotesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of convertible notes [Abstract]" } } }, "localname": "ScheduleOfConvertibleNotesAbstract", "nsuri": "http://www.rasna.com/20220331", "xbrltype": "stringItemType" }, "rasp_ScheduleOfPotentialCommonSharesIssuableUponTheExerciseOfOutstandingOptionsAndTheExerciseOfWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants [Abstract]" } } }, "localname": "ScheduleOfPotentialCommonSharesIssuableUponTheExerciseOfOutstandingOptionsAndTheExerciseOfWarrantsAbstract", "nsuri": "http://www.rasna.com/20220331", "xbrltype": "stringItemType" }, "rasp_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "rasp_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "rasp_TizianaLifeSciencesPlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tiziana Life Sciences PLC [Member]", "label": "TizianaLifeSciencesPlcMember", "terseLabel": "Tiziana Life Sciences PLC [Member]" } } }, "localname": "TizianaLifeSciencesPlcMember", "nsuri": "http://www.rasna.com/20220331", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r29", "r31", "r64", "r65", "r149", "r182" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r30", "r31", "r64", "r65", "r149", "r182" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r75", "r186" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rasna.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r75", "r80", "r130", "r186", "r248" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.rasna.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r269", "r281" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r10" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r67", "r68", "r69", "r193", "r194", "r195", "r219" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r187", "r196", "r197" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r43", "r49", "r165", "r232" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Accretion of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r49", "r165", "r173", "r174", "r234" ], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 5.0, "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "negatedLabel": "Accretion of debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total shares issuable upon exercise or conversion" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofpotentialcommonsharesissuableupontheexerciseofoutstandingoptionsandtheexerciseofwarrantsTable" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofpotentialcommonsharesissuableupontheexerciseofoutstandingoptionsandtheexerciseofwarrantsTable" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r6", "r61", "r110", "r113", "r118", "r127", "r132", "r133", "r134", "r136", "r137", "r138", "r139", "r140", "r141", "r143", "r144", "r206", "r211", "r224", "r244", "r246", "r264", "r276" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of preparation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r5", "r246", "r292", "r293" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r46", "r51", "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r46", "r225" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r24", "r270", "r280" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r67", "r68", "r219" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r8", "r183" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r8", "r246" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized; 68,908,003 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r57", "r208" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r52", "r53", "r54" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Description", "terseLabel": "Conversion of stock description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r145", "r146", "r147", "r148", "r157", "r158", "r159", "r161", "r162", "r163", "r164", "r165", "r171", "r172", "r173", "r174" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Promissory Note [Member]", "verboseLabel": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Schedule of convertible notes" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r7", "r265", "r277", "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable", "periodStartLabel": "Beginning balance" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Current", "terseLabel": "Convertible notes payable, net" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r41", "r251" ], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r58", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r160", "r166", "r167", "r168", "r177" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "CONVERTIBLE NOTES" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "auth_ref": [ "r7" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the total principal payments made during the annual reporting period.", "label": "Debt Instrument, Annual Principal Payment", "terseLabel": "Principal and accrued interest amount" } } }, "localname": "DebtInstrumentAnnualPrincipalPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r169" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Beneficial conversion feature related to issuance and extension of convertible notes" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest", "terseLabel": "Accrued Interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r21", "r170", "r233", "r235" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Interest charge, percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r21", "r147" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Carrying interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r22", "r148", "r222" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unearned discounts (other than cash or quantity discounts and the like), finance charges, and interest included in the face amount of receivables, that are shown as a deduction from the related receivables. For example, 1) finance charges booked as a receivable when a loan is made and recognized as income at a later date; and 2) interest charges deducted from the face loan amount, resulting in a discounted amount actually advanced to the borrower (wherein the receivable includes the amount actually advanced to the borrower and the as yet unearned interest income).", "label": "Deferred Discounts, Finance Charges and Interest Included in Receivables", "terseLabel": "Total interest charge" } } }, "localname": "DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "terseLabel": "Recognized an additional" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r49", "r129" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCashReceivedOnHedge": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash received during the period on settlement of a hedge.", "label": "Derivative, Cash Received on Hedge", "terseLabel": "Cash" } } }, "localname": "DerivativeCashReceivedOnHedge", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r27", "r28", "r31", "r223" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative liabilities", "verboseLabel": "Derivative liabilities in connection with issuance and extension of convertible notes" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet", "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r198" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "SHARE-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r9", "r63", "r135", "r137", "r138", "r142", "r143", "r144", "r240", "r267", "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Loan facility amount" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToOtherRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r17", "r63", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties classified as other, due within one year or the normal operating cycle, if longer.", "label": "Due to Other Related Parties, Current", "terseLabel": "Balance due to Eurema consulting services" } } }, "localname": "DueToOtherRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r63", "r240", "r268", "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties classified as other.", "label": "Due to Other Related Parties", "terseLabel": "Due to related party" } } }, "localname": "DueToOtherRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r17", "r63", "r135", "r137", "r138", "r142", "r143", "r144", "r240" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Related party payables" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r63", "r135", "r137", "r138", "r142", "r143", "r144", "r240", "r268", "r282" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Balance due to related party" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofconversionoftheoutstandingconvertibleloannotesTable" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r39", "r72", "r73", "r74", "r75", "r76", "r81", "r85", "r92", "r93", "r94", "r97", "r98", "r220", "r221", "r272", "r285" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic and net income/(loss) per share attributable to common shareholders (in Dollars per share)", "verboseLabel": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement", "http://www.rasna.com/role/ScheduleofconversionoftheoutstandingconvertibleloannotesTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r39", "r72", "r73", "r74", "r75", "r76", "r85", "r92", "r93", "r94", "r97", "r98", "r220", "r221", "r272", "r285" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income/ (loss) per share attributable to common shareholders (in Dollars per share)", "verboseLabel": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement", "http://www.rasna.com/role/ScheduleofconversionoftheoutstandingconvertibleloannotesTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r95", "r96" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income/(loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits and Share-Based Compensation", "terseLabel": "Share based compensation to employees" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Stock options [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofpotentialcommonsharesissuableupontheexerciseofoutstandingoptionsandtheexerciseofwarrantsTable" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r34", "r35", "r36", "r67", "r68", "r69", "r71", "r77", "r79", "r99", "r128", "r183", "r184", "r193", "r194", "r195", "r201", "r202", "r219", "r226", "r227", "r228", "r229", "r230", "r231", "r236", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofpotentialcommonsharesissuableupontheexerciseofoutstandingoptionsandtheexerciseofwarrantsTable", "http://www.rasna.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Common stock shares issued" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r49", "r178" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "terseLabel": "Gain on derivative liability", "verboseLabel": "Issuance of debt" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow", "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r49", "r175", "r176" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Gain on settlement of accounts payable" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow", "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r42" ], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r40", "r61", "r110", "r112", "r114", "r117", "r119", "r127", "r132", "r133", "r134", "r137", "r138", "r139", "r140", "r141", "r143", "r144", "r224" ], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r62", "r78", "r79", "r109", "r200", "r203", "r204", "r286" ], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r48" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due from Related Parties, Current", "negatedLabel": "Related party receivable" } } }, "localname": "IncreaseDecreaseInDueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties, Current", "terseLabel": "Related party payable" } } }, "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofconversionoftheoutstandingconvertibleloannotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense, Related Party", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss": { "auth_ref": [ "r273" ], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income or expense, including any amortization and accretion (as applicable) of discounts and premiums, including consideration of the provisions for loan, lease, credit, and other related losses.", "label": "Interest Income (Expense), after Provision for Loan Loss", "totalLabel": "Income/ (loss) from operations before income taxes" } } }, "localname": "InterestIncomeExpenseAfterProvisionForLoanLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentInterestRate": { "auth_ref": [ "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Rate of interest on investment.", "label": "Investment Interest Rate", "terseLabel": "Interest rate" } } }, "localname": "InvestmentInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r15", "r61", "r127", "r224", "r246", "r266", "r279" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r4", "r20", "r61", "r127", "r132", "r133", "r134", "r137", "r138", "r139", "r140", "r141", "r143", "r144", "r207", "r211", "r212", "r224", "r244", "r245", "r246" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current", "terseLabel": "Loan payable and accrued interest, related party" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r23", "r131" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r46", "r47", "r50" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow", "http://www.rasna.com/role/LiquidityandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r32", "r33", "r36", "r38", "r50", "r61", "r70", "r72", "r73", "r74", "r75", "r78", "r79", "r90", "r110", "r112", "r114", "r117", "r119", "r127", "r132", "r133", "r134", "r137", "r138", "r139", "r140", "r141", "r143", "r144", "r221", "r224", "r271", "r284" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income/(loss)", "totalLabel": "Net income / (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow", "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r72", "r73", "r74", "r75", "r81", "r82", "r91", "r94", "r110", "r112", "r114", "r117", "r119" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net Income, numerator, basic computation" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofconversionoftheoutstandingconvertibleloannotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r84", "r86", "r87", "r88", "r89", "r91", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net Income, numerator, diluted computation" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofconversionoftheoutstandingconvertibleloannotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r52", "r53", "r54" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Notes Issued", "terseLabel": "Notes issued" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails", "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating (income)/ expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating (income)/ expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r110", "r112", "r114", "r117", "r119" ], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income/ (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "auth_ref": [ "r179", "r216", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "Information by type of options indexed to an issuer's equity.", "label": "Option Indexed to Issuer's Equity [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityEquityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofpotentialcommonsharesissuableupontheexerciseofoutstandingoptionsandtheexerciseofwarrantsTable" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofpotentialcommonsharesissuableupontheexerciseofoutstandingoptionsandtheexerciseofwarrantsTable" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "GENERAL INFORMATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/GeneralInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income/(expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_InterestIncomeExpenseAfterProvisionForLoanLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "totalLabel": "Total other income/(expense)" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r49" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "terseLabel": "Non-cash interest expense" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r44" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from issuance of convertible notes payable" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r32", "r33", "r36", "r45", "r61", "r70", "r78", "r79", "r110", "r112", "r114", "r117", "r119", "r127", "r132", "r133", "r134", "r137", "r138", "r139", "r140", "r141", "r143", "r144", "r205", "r209", "r210", "r213", "r214", "r221", "r224", "r274" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss)", "verboseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/LiquidityandGoingConcernDetails", "http://www.rasna.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r185", "r239", "r240", "r241" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails", "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConvertibleNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r63", "r135", "r137", "r138", "r142", "r143", "r144", "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Related Party Transaction, Due from (to) Related Party", "terseLabel": "Balance due to related party" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r185", "r239", "r241", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/LiquidityandGoingConcernDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r237", "r238", "r240", "r242", "r243" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r199", "r250", "r295" ], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r12", "r184", "r246", "r278", "r290", "r291" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAppropriated": { "auth_ref": [ "r26", "r59", "r180", "r181", "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies.", "label": "Retained Earnings, Appropriated", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAppropriated", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/LiquidityandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsUnappropriatedMember": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "A segregation of retained earnings which is available for dividend distribution. Earnings not paid out as dividends but instead reinvested in the core business or used to pay off debt. Unappropriated profit is part of shareholder equity. Also called cumulative distributions or earned surplus or accumulated earnings or unappropriated profit.", "label": "Retained Earnings, Unappropriated [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsUnappropriatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r37", "r61", "r107", "r108", "r111", "r115", "r116", "r120", "r121", "r122", "r127", "r132", "r133", "r134", "r137", "r138", "r139", "r140", "r141", "r143", "r144", "r224", "r274" ], "calculation": { "http://www.rasna.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofpotentialcommonsharesissuableupontheexerciseofoutstandingoptionsandtheexerciseofwarrantsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r95" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/AccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of conversion of the outstanding convertible loan notes" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/AccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r48" ], "calculation": { "http://www.rasna.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r56", "r66" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/AccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r25", "r34", "r35", "r36", "r67", "r68", "r69", "r71", "r77", "r79", "r99", "r128", "r183", "r184", "r193", "r194", "r195", "r201", "r202", "r219", "r226", "r227", "r228", "r229", "r230", "r231", "r236", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofpotentialcommonsharesissuableupontheexerciseofoutstandingoptionsandtheexerciseofwarrantsTable", "http://www.rasna.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r67", "r68", "r69", "r99", "r251" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r25", "r183", "r184" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Beneficial conversion feature related to convertible notes" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments", "terseLabel": "New convertible notes issued" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofconvertiblenotesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Service charges" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r8", "r13", "r14", "r61", "r124", "r127", "r224", "r246" ], "calculation": { "http://www.rasna.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet", "http://www.rasna.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r247", "r249" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "LIQUIDITY AND GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/LiquidityandGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r100", "r101", "r102", "r103", "r104", "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofpotentialcommonsharesissuableupontheexerciseofoutstandingoptionsandtheexerciseofwarrantsTable" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Weighted average shares, denominator, diluted computation" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofconversionoftheoutstandingconvertibleloannotesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r84", "r94" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted weighted average common shares outstanding (in Shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r81", "r83" ], "lang": { "en-us": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number of Shares Issued, Basic", "terseLabel": "Weighted average shares, denominator, basic computation" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ScheduleofconversionoftheoutstandingconvertibleloannotesTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r81", "r94" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted average common shares outstanding (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.rasna.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3)(ii))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4519-111522" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21332-112643" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21346-112643" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(30)(a)(3)(ii))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.12)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(23)(a)(4)(i))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r296": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r297": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r298": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r299": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" } }, "version": "2.1" } ZIP 41 0001213900-22-033764-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-033764-xbrl.zip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